document incorporate reference table part portion registrant annual report shareholder fiscal year iii portion registrant proxy statement annual meeting table table caption item business general segment business geographic area consumer pharmaceutical medical device diagnostic geographic area raw material patent trademark seasonality competition research environment regulation property legal proceeding submission matter vote security holder executive officer registrant market registrant common equity relate shareholder matter select financial datum management discussion analysis financial condition result operation quantitative qualitative disclosure market risk financial statement supplementary data change disagreement accounting financialdisclosure iii director executive officer registrant executive compensation security ownership certain beneficial owner management certain relationship relate transaction control procedure exhibit financial statement schedule report form signature certification pursuant rule securities exchange act certification pursuant usc section report independent accountant exhibit index table form quarterly report available copy johnson johnson quarterly report form quarter current fiscal year exhibit provide charge shareholder submit write request secretary principal executive office company call report available day end quarter relate company sec filing available company website wwwjnjcom investor relation section item business general johnson johnson employ approximately people worldwide engage manufacture sale broad range product health care field operate company conduct business virtually country world johnson johnson primary interest historically currently product relate human health wellbee johnson johnson organize state new jersey johnson johnson organized principle decentralize management executive committee johnson johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie domestic international company span consumer pharmaceutical medical device diagnostic segment international subsidiary exception manage citizen country locate segment business johnson johnson worldwide business divide segment consumer pharmaceutical medical device diagnostic additional information require item incorporate reference narrative tabular graphic description segment operate result caption management discussion analysis result operation financial condition description segment consumer pharmaceutical medical device diagnostic operating result page johnson johnson annual report shareholder fiscal year consumer consumer segment principal product personal care product include nonprescription drug adult skin hair care product baby care product oral care product aid product woman health product nutritional product major brand include aveeno skin care product bandaid brand adhesive bandage benecol food product carefree panty shield clean clear teen skin care product compeed foot care product imodium antidiarrheal johnson baby line product johnson skin hair care product monistat remedy vaginal yeast infection adult child motrin ibuprofen product mylanta gastrointestinal product pepcid acid controller johnson johnson merck consumer pharmaceutical neutrogena skin hair care product tampon penaten natusan baby care products piz buin sundown sun care product reach toothbrush roc skin care product shower shower personal care product splenda noncaloric sugar substitute stayfree sanitary protection product broad family tylenol acetaminophen product viactivcalcium supplement consumer segment product market principally general public distribute wholesaler directly independent chain retail outlet world pharmaceutical pharmaceutical segment principal worldwide franchises antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology field product distribute directly wholesaler health care professional use prescription general public prescription drug antifungal field include nizoral ketoconazole sporanox itraconazole terazol terconazole daktarin miconazole nitrate antifungal product prescription drug antiinfective field include floxin ofloxacin levaquin levofloxacin prescription drug cardiovascular field include retavase reteplase recombinant biologic cardiology care product treatment acute myocardial infarction improve blood flow heart reopro abciximab treatment acute cardiac disease prescription drug dermatology field include retina micro tretinoin dermatological cream acne prescription drug gastrointestinal field include aciphex rabeprazole sodium proton pump inhibitor treat erosive gastroesophageal reflux disease gerd duodenal ulcer company derive service revenue product copromote eisai imodium loperamide hcl antidiarrheal motilium domperidone gastrointestinal mobilizer remicade infliximab novel monoclonal antibody treatment certain crohn disease patient remicade indicate treatment rheumatoid arthritis prescription drug hematology field include procrit epoetin alfa sell outside eprex biotechnology derive version human hormone erythropoietin stimulate red blood cell production account company total revenue prescription drug immunology field include orthoclone okt muromonabcd reverse rejection kidney heart liver transplant prescription drug neurology field include reminyl galantamine topamax topiramate stugeron cinnarizine prescription drug oncology field include doxil doxorubicin anticancer treatment ergamisol levamisole hydrochloride colon cancer drug leustatin cladribine hairy cell leukemia prescription drug pain management field include duragesic fentanyl transdermal system sell abroad durogesic transdermal patch chronic pain ultracet tramadol hydrochlorideacetaminophen shortterm management acute pain prescription drug psychotropic central nervous system field include risperdal risperidone haldol haloperidol concerta methylphenidate attention deficithyperactivity disorder prescription drug urology field include ditropan oxybutynin treatment overactive bladder prescription drug contraceptive field include orthoevra norelgestrominethinyl estradiol transdermal system orthonovum norethindroneethinyl estradiol tricilest norgestimateethinyl estradiol sell ortho tricyclen group oral contraceptive sale large distributor amerisourcebergen corp mckesson hboc cardinal distribution account respectively total revenue medical device diagnostic medical device diagnostic segment include broad range product direction physician nurse therapist hospital diagnostic laboratory clinic product include ethicon wound care surgical sport medicine woman health product ethicon endosurgery minimally invasive surgical product cordis circulatory disease management product lifescan blood glucose monitoring product orthoclinical diagnostic professional diagnostic product depuy orthopaedic joint reconstruction spinal product vistakon disposable contact lense distribution health care professional market directly surgical supply dealer geographic area international business johnson johnson conduct subsidiary locate country outside united states sell product virtually country world product sell international business include describe description segment consumer pharmaceutical medical device diagnostic principal market product method distribution international business vary country culture product sell international business include develop united states develop bysubsidiarie abroad investment activity country outside united states subject high risk comparable domestic activity investment commercial climate influence restrictive economic policy political uncertainty raw material raw material essential johnson johnson business generally readily available multiple source patent trademark johnson johnson practice obtain patent protection product process possible johnson johnson own license number patent relate product manufacturing process aggregate believe material importance operation business believe patent relate procritexprex single patent relate group patent material relation johnson johnson johnson johnson practice sell product trademark obtain protection trademark available mean johnson johnson trademark protect registration united states country product market johnson johnson consider trademark aggregate material importance operation business seasonality worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research grant competition product line johnson johnson company compete company large small locate united states abroad competition strong line regard number size compete company involve competition research involve development new product process improvement exist product process particularly significant result time time product process obsolescence development new improved product important johnson johnson success area business competitive environment require substantial investment continue research multiple sale force addition win retention customer acceptance johnson johnson consumer product involve heavy expenditure advertising promotion sell research research activity important segment johnson johnson business major research facility locate united states australia belgium brazil canada germany switzerland united kingdom cost johnson johnson worldwide research activity relate development new product improvement exist product technical support product compliance governmental regulation protection consumer amount million fiscal year respectively cost charge directly income year incur research sponsor johnson johnson environment past year johnson johnson subject variety federal state local environmental protection measure johnson johnson believe operation comply material respect applicable environmental law regulation johnson johnson compliance requirement expect material effect capital expenditure earning competitive position regulation johnson johnson business subject vary degree governmental regulation country operation conduct general trend regulation increase stringency unitedstate drug device diagnostic cosmetic industry long subject regulation federal state local agency primarily product safety efficacy advertising labeling exercise broad regulatory power food drug administration fda continue result increase amount test documentation require fda clearance new drug device correspond increase expense product introduction similar trend product process regulation evident number major country outside united states especially european economic community effort continue harmonize internal regulatory system cost human health care continue subject study investigation regulation governmental agency legislative body united states countries united states attention focus drug price profit program encourage doctor write prescription particular drug recommend particular medical device absence new government regulation manage care potent force market place likely increase attention pay drug medical device price appropriate drug medical device utilization quality health care regulatory agency purview johnson johnson operate administrative power subject johnson johnson action product recall seizure product civil criminal sanction case johnson johnson deem advisable initiate product recall voluntarily item property johnson johnson worldwide subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment johnson johnson business approximately follow table caption square foot segment thousand consumer pharmaceutical medical device diagnostic worldwide total table united states facility consumer segment pharmaceutical segment medical device diagnostic segment johnson johnson manufacturing operation outside united states conduct facility serve segment business location manufacture facility major geographic area world follow table caption number square feet geographic area facility thousands united states europe western hemisphere exclude usa africa asia pacific worldwide total table addition manufacturing facility discuss johnson johnson maintain numerous office warehouse facility world research facility discuss item business researchjohnson johnson generally seek manufacture facility principally location abroad lease office warehouse facility lease johnson johnson property maintain good operating condition repair utilize information lease obligation note rental expense lease commitment note consolidated financial statement johnson johnson annual report shareholder fiscal year segment information addition johnson johnson property plant equipment contain johnson johnson annual report shareholder fiscal year item legal proceeding information set forth note legal proceeding note consolidated financial statement johnson johnson annual report shareholder fiscal year incorporate reference company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state law primary relief seek cost past future remediation feasible predict determine outcome proceeding opinion company proceeding material adverse effect result operation cash flow financial position company item submission matter vote security holder applicable executive officer registrant list executive officer johnson johnson march indicate employee company affiliate hold position indicate past year family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal information regard director company include follow executive officer director incorporate reference page johnson johnson proxy statement date march table caption age position robert darretta member board director member executive committee executive vice president chief financial officer russell deyo member executive committee vice president administrationa michael dormer member executive committee worldwide chairman medical devices groupb roger fine member executive committee vice president general counselc colleen goggin member executive committee worldwide chairman consumer personal care groupd joann heffernan heisen member executive committee vice president chief information officere james lenehan vice chairman board directors president member executive committee table table caption age position brian perkins member executive committee worldwide chairman consumer pharmaceutical nutritional groupf peterson phd member executive committee chairman research development pharmaceutical groupg christine poon member executive committee worldwide chairman pharmaceuticals grouph william weldon chairman board directors chief executive officer chairman executive committee robert wilson senior vice chairman board directorsi table deyo join company associate general counsel member executive committee vice president administration dormer join company company group chairman worldwide franchise chairman depuy codman company acquire depuy inc time acquisition chief operating officer depuy inc dormer serve president depuy international ltd dormer member executive committee franchise group chairman medical devices april dormer name worldwide chairman medical device group fine join company member executive committee vice president administration vice president general counsel goggins join company hold position president personal product company name president johnson johnson consumer product company company group chairman north america johnson johnson consumer product goggin member executive committee worldwide chairman consumer personal care group heisen join company treasurer controller member executive committee vice president chief information officer perkin join company hold position president mcneil consumer product company company group chairman otc pharmaceutical member executive committee worldwide chairman consumer pharmaceutical nutritional group peterson join company vice president drug discovery johnson pharmaceutical research institute name group vice president pharmaceutical research institute april president november peterson name chairman research development pharmaceuticals group peterson member executive committee poon join company company group chairman pharmaceuticals group poon member executive committee worldwide chairman pharmaceuticals group prior join company serve management position bristolmyer squibb year recently president international medicine president medical devices wilson join company serve sale marketing management position appoint company group chairman appoint executive committee appoint chairman sector operating committee appoint vice chairman board director assume expand responsibility vice chairman executive committee name senior vice chairman board director item market registrant common equity relate shareholder mattersthe information call item incorporate reference material caption management discussion analysis result operation financial condition share repurchase dividend common stock market price johnson johnson annual report shareholder fiscal year item select financial datum information call item incorporate reference material caption summary operation statistical data johnson johnson annual report shareholder fiscal year item management discussion analysis financial condition result operation information call item incorporate reference narrative tabular graphic material include material caption management discussion analysis result operation financial condition page johnson johnson annual report shareholder fiscal year item quantitative qualitative disclosure market risk information call item incorporate reference material caption management discussion analysis result operation financial condition financial position capital resources johnson johnson annual report shareholder fiscal year item financial statement supplementary datum information call item incorporate reference consolidate financial statement note thereto material caption independent auditor report page johnson johnson annual report shareholder fiscal year item change disagreement accountant account financial disclosure applicable iii item director executive officer registrant information call item incorporate reference material caption election director nominee page johnson johnson proxy statement date march material hereof caption executive officer registrant material caption section beneficial ownership report compliance johnson johnson proxy statement date march item executive compensation information call item incorporate reference follow section johnson johnson proxy statement date march election director director fee committee meeting page compensation committee report executive compensation page shareowner return performance graph page executive compensation page item security ownership certain beneficial owner management information call item incorporate reference material caption election director stock ownershipcontrol page johnson johnson proxy statement date march item certain relationship relate transaction applicable item control procedure disclosure control day filing report company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure arethe control procedure company design ensure record process summarize report timely manner information company disclose report file securities exchange act william weldon chairman chief executive officer robert darretta executive vice president chief financial officer review participate evaluation base evaluation messr weldon darretta conclude date evaluation company disclosure control procedure effective internal control date evaluation describe significant change company internal control factor significantly affect control include corrective action regard significant deficiency material weakness item exhibit financial statement schedule report form follow document file report financial statement follow consolidated financial statement note thereto independent auditor report page johnson johnson annual report shareholder fiscal year incorporate reference consolidate balance sheet end fiscal year consolidated statement earning fiscal year consolidated statement equity fiscal year consolidated statement cash flow fiscal year note consolidated financial statement independent auditor report financial statement schedule schedule valuation qualifying account schedule list omit require applicable exhibit require file item regulation information call item incorporate reference exhibit index report report form report form file october include press release statement amgen arbitration report form file december include press release statement change european labeling eprexerypo report form file december fund company pension plan report form file january include press release statement amgen arbitration report resignation john snow board director report form file march include management discussion analysis financial condition result operation independent auditor report johnson johnson subsidiaries schedule valuation qualify accountsfiscal year end december december december dollar million table caption addition balance charge deduction reserve balance begin cost end period expensesa description period reserve deduct account receivable trade reserve doubtful account writeoff recovery currency adjustment reserve customer rebate customer rebate allow currency adjustment reserve cash discount cash discount allow currency adjustment reserve deduct account receivable trade reserve doubtful account writeoff recovery currency adjustment reserve customer rebate customer rebate allow currency adjustment reserve cash discount cash discount allow currency adjustment reserve deduct account receivable trade reserve doubtful account writeoff recovery currency adjustment reserve customer rebate customer rebate allow currency adjustment reserve cash discount cash discount allow currency adjustment table charge relate customer rebate cash discount reflect reduction sale customer signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize date march johnson johnson registrant weldon weldon chairman board directors chief executive officer pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate table caption signature title date weldon chairman board director march chief executive officer weldon director principal executive officer darretta executive vice president chief march financial officer director darretta principal financial officer cosgrove controller march cosgrove burrow director march burrow cullen director march cullen director march folkman jordan director march jordan langbo director march langbo lenehan vice chairman board director march president director lenehan table table caption signature title date mullin director march mullin satcher director march satcher schacht director march schacht singer director march singer wilson senior vice chairman board march directors director wilson table certification chief executive officer pursuant rule securities exchange act william weldon certify review annual report johnson johnson registrant base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule registrant design disclosure control procedure ensure material information relate registrant include consolidated subsidiary known entity particularly period annual report prepare evaluate effectiveness registrant disclosure control procedure date day prior filing date annual report evaluation date present annual report conclusion effectiveness disclosure control procedure base evaluation evaluation date registrant certify officer disclose base recent evaluation registrant auditor audit committee registrant board director person perform equivalent function significant deficiency design operation internal control adversely affect registrant ability record process summarize report financial datum identify registrant auditor material weakness internal control fraud material involve management employee significant role registrant internal control registrant certify officer indicate annual report significant change internal control factor significantly affect internal control subsequent date recent evaluation include corrective action regard significant deficiency material weakness william weldon william weldon chief executive officer date march certification chief financial officer pursuant rule securities exchange act robert darretta certify review annual report johnson johnson registrant base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule registrant design disclosure control procedure ensure material information relate registrant include consolidated subsidiary known entity particularly period annual report prepare evaluate effectiveness registrant disclosure control procedure date day prior filing date annual report evaluation date present annual report conclusion effectiveness disclosure control procedure base evaluation evaluation date registrant certify officer disclose base recent evaluation registrant auditor audit committee registrant board director person perform equivalent function significant deficiency design operation internal control adversely affect registrant ability record process summarize report financial datum identify registrant auditor material weakness internal control fraud material involve management employee significant role registrant internal control registrant certify officer indicate annual report significant change internal control factor significantly affect internal control subsequent date recent evaluation include corrective action regard significant deficiency material weakness robert darretta robert darretta chief financial officer date march certification chief executive officer pursuant usc section undersign william weldon chief executive officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifies company annual report fiscal year end december report fully complie requirement ofsection securities exchange act information contain report fairly present material respect financial condition result operation company william weldon william weldon chief executive officer date march certification accompanie report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend certification chief financial officer pursuant usc section undersign robert darretta chief financial officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifies company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company robert darretta robert darretta chief financial officer date march certification accompanie report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend report independent accountant financial statement schedule shareholder board directors johnson johnson audits consolidated financial statement refer report date january note date february appear annual report shareholder johnson johnson report consolidated financial statement incorporate reference annual report include audit financial statement schedule list item opinion financial statement schedule present fairly material respect information set forth read conjunction relate consolidated financial statement pricewaterhousecooper llp pricewaterhousecooper llp new york new york january exhibit index tablecaption reg exhibit table description item exhibit restate certificate incorporation date april incorporate reference exhibit registrant annual report year end december aii certificate amendment restate certificate incorporation company date incorporate reference exhibit registrant annual report year end january aiii certificate amendment restate certificate incorporation company date incorporate reference exhibit aiii registrant annual report year end december aiv certificate amendment restate certificate incorporation company effective incorporate reference exhibit registrant form quarterly report quarter end july bylaw company amend effective june incorporate reference exhibit registrant form quarterly report quarter end july request security exchange commission registrant furnish copy instrument define right holder long term debt registrant stock option plan nonemployee director incorporate reference exhibit registrant annual report year end december stock option plan amend file document stock option plan amend incorporate reference exhibit registrant annual report year end january stock option plan amend incorporate reference exhibit registrant annual report year end december stock compensation plan incorporate reference exhibit registrant annual report year end december executive incentive plan amend incorporate reference exhibit registrant annual report year end december domestic deferred compensation certificate extra compensation plan amend incorporate reference exhibit registrant annual report year end december defer fee plan director amend file document executive income deferral plan amend file document excess saving plan incorporate reference exhibit registrant annual report year end december supplemental retirement plan incorporate reference exhibit registrant annual report year end january executive life insurance plan incorporate reference exhibit registrant annual report year end january stock option gain deferral plan incorporate reference exhibit registrant annual report year end january estate preservation plan incorporate reference exhibit registrant annual report year end january table table captionreg exhibit table description item exhibit letter agreement date june company larsen respect postemployment arrangement file document consulting agreement company judah folkman member board file document statement computation ratio earning fix charge file document page company annual report shareholder fiscal year portion annual report incorporate reference report deem file file document subsidiary file document consent independent accountant file document annual report form johnson johnson saving plan file june cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement file document table management contract compensatory plan arrangement require file exhibit form pursuant item report copy exhibit list provide charge shareholder submit write request specify desire exhibit secretary principal executive office company text document document typeexb sequence filenameyexvwbtxt description stock option plan amend text exhibit johnson johnson stock option plan amend february purpose purpose johnson johnson stock option plan plan promote interest johnson johnson company ensure continuity management increase incentive officer executive employee responsible major contribution effective management facilitate acquisition equity interest company reasonable term administration plan shall administer compensation committee board directors committee committee shall consist director person shall eligible continue serve member committee person nonemployee director mean rule general rule regulation securities exchange act amend outside director mean section internal revenue code amend internal revenue code committee shall power select optionee establish number share term applicable option construe provision plan adopt rule regulation govern administration plan board director discretion shall authority amend plan term option issue hereunder necessity obtain approval shareowner approval require law notwithstanding forego stock split adjustment orother change corporate structure share company contemplate section hereof company shall low exercise price option grant plan grant option hereunder replacement option previously grant high exercise price approval shareowner eligibility eligible participate plan select committee follow director officer key employee company domestic subsidiary key employee subsidiary outside united states key employee joint venture operation company subsidiarie key employee joint venture partner assign joint venture case optionee shall select basis demonstrate ability contribute substantially effective management financial performance company subsidiary event shall option grant individual immediately option grant consider stock possess combine voting power class stock johnson johnson subsidiary mean section internal revenue code allotment share common stock company par value share subject grant option plan calendar year shall exceed equal percent issue share company common stock include treasury share january year plus number share available grant previous year plan subject grant previous year number share cover option grant plan option lapse expired terminate previous year exercise notwithstanding forego million share aggregate shall available issuance incentive stock option plan total number share award plan optionee year shall exceed less total share allot plan year million share committee discretion issue exercise option treasury share authorize unissued share effective date term plan plan approve shareowner company shall effective april option shall grant pursuant plan later april right optionee option theretofore grant affected unexpired option continue force operation option lapse terminate accordance term condition term condition aall option follow shall apply option grant plan option price option price share stock option shall determine committee shall fair market value date option grant fair market value shall determine prescribe internal revenue code regulations time exercise option committee shall establish time time option period stock option exercise part specify time time committee respect optionee employment terminate reason death disability retirement committee discretion accelerate time times particular stock option hold say optionee exercise time time early originally provide said option case exercise stock option shall subject provision section bii ciii case committee shall determine time grant later extent circumstance delivery share issuable connection exercise nonqualified option defer election optionee iii payment entire option price pay time option exercise option exercise prior termination employment committee shall discretion arrange payment price installment case committee shall obtain evidence optionee obligation establish interest rate require security deem appropriate adequate protection company nontransferability option specify committee contrary option term shall transferable optionee law descent distribution shall exercisable optionee lifetime optionee committee manner establish committee provide transfer payment consideration nonqualified option optionee member optionee immediate family trust partnership beneficiary member optionee immediate family case option shall exercisable transferee purpose provision optionee immediate family shall mean holder spouse child grandchildren adjustment event recapitalization company event reorganization recapitalization stock split stock dividend combination share merger consolidation right offering change corporate structure share company board director shall adjustment deem equitably require number kind share authorize plan number kind share cover option grant number share award optionee year option price right termination employment event termination employment cause death disability retirement right exercise stock option shall cease accrue include date termination define committee shall specify right shall remain exercisable period month date termination long period exceed year committee shall provide event termination employment death disability right exercise stock option shall cease accrue include date termination committee shall specify right shall remain exercisable period year long period exceed term option committee shall provide notwithstanding event termination employment death disability occur optionee year service unexercised unexercisable portion stock option exercise remain term option time extent optionee exercise stock option optionee employment terminate event retirement unrelated termination cause define shall govern provision right exercise stock option shall cease accrue include date termination committee shall specify right shall remain exercisable aperiod year long period exceed term option committee shall provide provide event optionee employ competitor define year date retirement right exercisable date month commencement employment competitor notwithstanding event retirement unrelated termination cause shall govern provision occur optionee year service unexercised unexercisable portion stock option exercise remain term stock option time extent optionee exercise stock option optionee employment terminate provide event optionee employ competitor year date retirement unexercisable portion stock option shall terminate immediately right exercisable date month commencement employment competitor stock option shall event exercise expiration year date option grant early date specify option addition stock option grant month termination employment cause whatsoever shall void committee shall provide plan term termination cause shall mean optionee termination company subsidiarie connection violation federal state law dishonesty willful deliberate failure optionee perform hisher employment duty material respect event include existence conflict interest management compensation committee determine committee shall sole discretion determine termination cause exist determination shall final term employ competitor shall mean optionee engage activity provide service director employee advisor consultant corporation entity competitor company subsidiary management compensation committee shall sole discretion determine optionee employ competitor determination shall final iii term date termination shall mean date optionee active employment status specifically event optionee cover severance agreement arrangement date termination shall day date active employment date correspond end severance period nonqualified stock option committee discretion grant option plan qualify incentive stock option section internal revenue code addition term condition set forth section follow term condition shall govern option portion thereof extent qualify form payment payment option price option portion thereof qualifying incentive stock option shall cash discretion committee common stock company value fair market value shall determine committee combination common stock cash payment option price common stock acquire company compensation plan mean opinion accounting principle board common stock accept payment optionee beneficially own suchcommon stock month increase year common stock acquire incentive stock option prior payment period option exercise period nonqualified stock option term shall year date option grant specified committee incentive stock option committee discretion grant option plan qualify incentive stock option section internal revenue code addition term condition set forth section follow term condition shall govern option portion thereof extent qualify maximum fair market value incentive stock option aggregate fair market value determine time option grant common stock optionee stock option vested calendar year incentive stock option plan company subsidiary shall exceed form payment payment option price incentive stock option shall cash common stock company value fair market value shall determine committee combination common stock cash payment option price common stock acquire company compensation plan mean opinion accounting principle board common stock accept payment optionee beneficially own common stock month increase year common stock acquire incentive stock option prior payment iii period option exercise period incentive stock option term shall year date option grant specified committee option nonemployee director notwithstanding forego event inconsistency term condition follow term condition follow term condition shall govern stock option grant nonemployee directors board directors committee shall establish time time option period stock option exercise part specify time time committee provide option shall exercisable completion nonemployee director board service nonemployee director complete service director company reason death option exercise time remainder option term iii event nonemployee director death regardless serve director option exercise subject provision section year death estate person acquire option inheritance devise right shall lapse text document document typeexh sequence filenameyexvwhtxt descriptiondeferred fee plan director amend text exhibit johnson johnson defer fee plan director amend december purpose purpose johnson johnson defer fee plan director plan provide outside director johnson johnson company opportunity defer receipt compensation earn director date follow termination service provision opportunity design aid company attract retain member board director person ability experience judgment contribute company effective date original effective date plan january plan amend entirety effective january december eligibility director company employee company relate company shall participate plan defer compensation account defer compensation account shall establish director deferral participant shall effective january require defer receipt thousand dollar hisher annual fee serve board director require deferral addition participant elect defer receipt specify remain compensation payable participant serve board director serve committee board director company equal defer compensation credit participant deferred compensation account quarterly basis dividend payment date quarter payment date event shall dividend payment date quarter payment date shall deem business day quarter defer compensation account hypothetical investment option require deferral specify participant pursuant term paragraph section amount elect defer plan calendar year shall credit participant deferred compensation account convert equivalent unit johnson johnson common stock company stock adjust compensation defer invest company stock payment date date final payment pursuant section hereof company stock equivalent unit number company stock equivalent unit shall determine dividing compensation payable average high low price company stock trade new york stock exchange trading day immediately prior payment date report bloomberg financial reporting service select company sole discretion number company stock equivalent unit include participant deferred compensation account shall adjust reflect dividend value account shall adjust reflect increase decrease market value resulted fund equal balance participant deferred compensation account invest company stock obligate company purchase company stock company stock purchase shall remain sole property company respect require deferral election participant provide section defer compensation account credit interest payment date date final payment pursuant section hereof rate equal annual rate growth investment johnson johnson certificate extra compensation plan cec plan prior year provide computation say growth rate shall include dividend equivalent pay cec plan election permit section shall available participant participant plan december respect company stock equivalent unit defer compensation account company shall credit account dividend payment date declare respect company stock number company stock equivalent unit equal product dividend share company stock payable dividend payment date multiply number company stock equivalent unit credit account applicable dividend record date divide averageof high low price company stock trade new york stock exchange trading day immediately prior dividend payment date report bloomberg financial reporting service select company sole discretion fractional company stock equivalent unit shall carry forward fractional dividend equivalent unit shall payable thereon account balance company stock equivalent unit company retirement plan nonemployee director transfer hisher defer compensation account plan january reason termination retirement plan shall treat purpose plan require deferral time election deferral require deferral shall time hold company stock equivalent unit participant change compensation defer andor option elect section respect hisher account deferral subsequent year annually december complete form provide company purpose change shall effective january follow year participant elect change hisher investment option available section participant account shall value december value enter hisher account new investment option follow january change company stock equivalent unit trading day follow january shall value defer compensation account value participant deferred compensation account shall case include compensation defer interest credit thereon adjustment dividend increase decrease market value company stock pursuant option select section require plan company stock trade date calculation common stock equivalent unit plan precede date stock trade shall utilize payment defer compensation participant completion service member board director completion date participant event participant death name beneficiary hisher estate shall entitle receive cash lump sum value hisher defer compensation account completion date participant elect pursuant provision section defer payment hisher defer compensation account completion date company stock equivalent unit shall value average high low price company stock trade new york stock exchange trading day immediately prior date report bloomberg financial reporting service select company sole discretion withdrawal participant deferred compensation account prior completion date value participant deferred compensation account shall subject election pursuant section pay soon practicable follow completion date death deferral election addition deferral election refer participant elect manner provide continue defer receipt hisher defer compensation account hisher completion date value participant account hisher completion date defer taxable year follow completion date installment elect installment payment immediately completion date defer taxable year installment payment annually manner describe approximately equal amount balance account minimum number installment maximum number provide payment shall year completion date participant elect defer value hisher account completion date percentage increment defer installment payment shall cash follow additional rule shall apply immediate lump sum payment participant receive value hisher account calendar month hisher completion date defer lump sum payment participant receive value hisher account january year heshe elect receive payment immediate commencement installments participant receive installment calendar month hisher completion date subsequent installment january year defer commencement installment participant receivethe subsequent installment january year event death participant company payment balance account soon administratively practical single lump sum payment designate beneficiary hisher estate make payment january value participant account trading day month shall utilize deferral follow completion date shall invest company stock equivalent unit describe section extent participant account credit annual growth rate investment cec plan describe section account shall convert common stock equivalent unit completion date election participant defer payment elect installment hisher defer compensation account completion date minimum month prior completion date election revise revoke month prior completion date time election revoke revise notwithstanding implementation plan exception participant completion date participant deferral installment election minimum month calendar year prior completion date example participant completion date april deferral andor installment election later december election defer andor receive installment payment revise revoke prior permissible date make election time election revoke revise election defer payment andor pay installment completion date effective file extra compensation service form utilize purpose election require deadline shall disregard designation beneficiary participant time time write file secretary company designate legal natural person person designate contingently successively payment participant deferred compensation account participant die prior receipt payment account beneficiary designation effective sign form file secretary company participant alive cancel beneficiary designation form file early participant fail designate beneficiary provide designated beneficiary die participant complete payment defer compensation account account shall pay estate die participant designate beneficiary soon practicable death participant right unsecure right participant receive payment provision plan shall unsecured claim general asset company provision contain plan shall construe participant beneficiary time security interest defer compensation account asset trust company benefit participant beneficiary statement account statement send participant soon practical follow end year value hisher defer compensation account december year assignability right receive payment hereunder shall transferable assignable participant beneficiary law descent distribution administration plan plan shall administer committee appoint responsible board director committee shall consist director company committee shall act vote write consent majority member amendment termination plan plan time time time amend modify terminate compensation committee board director board director company amendment modification termination shall consent participant adversely affect participant accrual defer compensation account govern law agreement shall govern construe accordance law state new jersey text document document typeexi sequence filenameyexvwitxt descriptionexecutive income deferral plan amend text exhibit johnson johnson executive income deferral plan amend december johnson johnson executive income deferral plan plan intend permit select group executive defer income immediately payable compensation andor incentive plan johnson johnson company administration plan administer compensation committee company board director committee shall responsibility determine investment time time available plan shall review investment option year committee shall decision affect timing price defer award hereinafter define participant subject section security exchange act amend delegate authority plan eligibility eligibility defer income amount plan initially limit members executive committee company committee time time expand eligibility defer compensation plan executive company committee authority refuse permit executive participate plan elect defer payment committee determine participation jeopardize plan compliance applicable law plan status hat plan erisa deferral income deferral account estate preservation plan participant elect defer percent annual salary percent cash andor stock awards company executive incentive plan iii percent dividend equivalent pay company certificate extra compensation cec plan percent dividend equivalent pay deferred gain share company stock option gain deferral plan amount defer know deferred award direct election participant income deferral account estate preservation plan describe participant decision defer plan september year prior commencement fiscal year compensation bonus incentive payment dividend equivalent monie defer earn notwithstanding forego require notice period election respect amount defer shall govern notice election provision stock option gain deferral plan election defer pursuant section shall effective timely file extra compensation service form utilize purpose participant shall designate multiple defer award portion allocate investment option available plan participant change investment option defer award credit income deferral account month change effective day month follow month participant request change allocation file extra compensation service determine maximum amount defer participant plan committee shall account include commitment participant estate preservation plan extent salary andor cash award company executive incentive plan insufficient meet prior deferral commitment participant plan estate preservation plan deferral commitment plan shall reduce accordingly thedeferral commitment estate preservation plan fund election defer dividend equivalent company cec plan apply election apply cec contract reverse order issuance defer award shall hold account regardless form compensation plan earn cease employee company participant event participant death name beneficiary hisher estate shall entitle receive cash lump sum value hisher income deferral account date termination participant elect pursuant provision section defer payment hisher income deferral account retirement notwithstanding participant fiscal year name executive officer proxy statement report purpose reason hisher chief executive officer company high compensate officer chief executive officer payment income deferral account year shall postpone date day january follow fiscal year provide fund income deferral account shall deemed invest year treasury bill rate describe date retirement payment investment income deferral account election participant amount income deferral account invest utilize investment option set forth amount defer month include stock award value credit participant income deferral account effective day month amount defer estate preservation plan separate distinct amount defer income deferral account common stock equivalent unit amount elect deferred investment option shall convert equivalent unit company common stock common stock compensation defer invest common stock common stock equivalent unit number common stock equivalent unit shall determine dividing compensation dividend equivalent defer average high low price common stock trade new york stock exchange trading day immediately precede trading day month report bloomberg financial reporting service select company sole discretion company shall credit participant income deferral account effective trading month number partial share company common stock determine time shall share company common stock actually purchase earmark income deferral account participant shall right shareowner respect share credit income deferral account number common stock equivalent unit include participant income deferral account shall adjust reflect payment dividend increase decrease market value resulted fund equal defer actually invest common stock value company common stock purpose investment redesignation describe section shall closing price company common stock new york stock exchange trading day immediately precede trading day month participant redesignation request receive extra compensation service report determined shall effective trading day month distributions cash value equivalent share company common stock value closing price company common stock new york stock exchange trading date precede distribution date report determined event reorganization stock split stock dividend combination share merger consolidation right offering change corporate structure share company committee shall adjustment deem appropriate number kind share company common stock credit participant income deferral account balanced fund amount elect deferred option shall deem invest credit investment rate return earn balanced fund option company saving plan successor fund balanced fund share shall purchase earmarked participant accountc year treasury bill rate amount elect deferred option shall deem invest interest bear account bear interest year treasury bill rate compound monthly purpose plan year treasury bill rate shall interest rate year treasury bill trading day precede calendar year provide financial reporting service shall select company sole discretion rate shall adjust annually treasury bill actually purchase earmark participant account redesignation investment option income deferral account participant redesignate amount previously credit income deferral account investment option available plan participant wish redesignate particular investment option time redesignate investment option redesignation investment place day prior schedule distribution plan follow additional rule shall apply respect redesignation previously credit amount permit frequencyredesignation participant consecutive month period extent redesignationredesignation participant multiple investment redesignation timingredesignation shall place effective day month follow month participant write redesignation receive extra compensation service value company common stock purpose investment redesignation shall average high low trading price common stock new york stock exchange report determined trading day immediately precede trading day prior month special rule redesignation common stock equivalent unit previously credit income deferral account material nonpublic informationthe committee sole discretion advice counsel time rescind redesignation common stock equivalent unit redesignation participant time redesignation possession material nonpublic information respect company committee estimation benefit information timing redesignation committee determination shall final bind event rescission participant income deferral account shall return status redesignation occur notwithstanding committee shall rescind redesignation fact review participant general counsel company designee prior redesignation general counsel designee conclude participant possession material nonpublic information participant subject section securities exchange act redesignate income deferral account common stock equivalent unit applicable window period respect release quarterly annual statement sale earning company iii redesignation amount income deferral account shall common stock equivalent unit month discretionary opposite way transaction common stock hold participant company saving plan estate preservation plan participant transfer amount income deferral account balance estate preservation plan accordance term estate preservation plan transfer estate preservation plan amount transfer income deferral account distribution income deferral account participant employment terminate reason include death disability participant eligible retire active service company pension plan income deferral account automatically pay lump sum soon administratively feasible month follow termination employment distribution cash value equivalent share company common stock value average high low trading price common stock new york stock exchange report determined trading day immediately precede trading day month employment wasterminate post retirement deferral election participant provide payment sum participant hisher retirement defer pay single lump sum installment lump sum payment defer taxable year follow participant retirement date installment payment elect installment payment immediately retirement defer taxable year installment payment annually manner describe approximately equal installment amount value balance income deferral account plus accrue interest divide number remain installment minimum number annual installment maximum number participant elect defer value hisher total income deferral account retirement percentage increment payment amount income deferral account pursuant section shall subject provision sentence section follow additional rule shall apply respect payment immediate lump sum payment participant receive value income deferral account calendar month retirement effective date participant retire prior determination prior year incentive plan award receive estimate value remainder pay shortly final value determine defer lump sum payment participant receive value income deferral account plus accrue interest january year elect receive payment immediate commencement installments participant receive installment calendar month hisher retirement effective date subject provision sentence section subsequent installment plus accrue interest pay january year defer commencement installment participant receive subsequent installment plus accrue interest january year respect amount defer andor pay installment interest shall pay company effective date retirement date payment interest rate defer andor installment payment participant shall fix date retirement shall rate rounded decimal place offer report financial reporting service company sole discretion shall select effective retirement date united states treasury instrument period comparable length period deferral andor installment payment interest shall compound semiannually calendar day june december year instrument quote average rate shall utilize way example election receive installment year comparable year treasury rate shall utilize election defer commencement installment year installment pay year comparable year treasury rate shall utilize established interest rate shall remain fix period deferral andor installment event death participant follow retirement company payment balance hisher income deferral account plus accrue interest soon administratively practical single lump sum payment designate beneficiary subject provision sentence section event deferral installment election section total income deferral account pay accordance provision section lump sum payment soon practical follow participant retirement effective date election participant defer payment elect installment hisher account hisher effective retirement date minimum month prior date retirement date election revise revoke month prior retirement date month period prior retirement date election irrevocable revoke revisednotwithstande plan inception exception participant retirement effective date january december participants retirement effective date prior june deferral andor installment election minimum month calendar year prior retirement date participant retirement date july december election month prior retirement date example participant retire april deferral andor installment election later december retirement date august election later january election defer andor receive installment payment revise revoke prior permissible date make election time election revoke revise election defer payment andor pay installment effective timely file extra compensation service form utilize purpose election require deadline shall disregard estate preservation plan describe section participant elect transfer portion balance income deferral account estate preservation plan accordance term estate preservation plan event election participant income deferral account shall reduce direct participant december year transfer occur transfer income deferral account estate preservation plan shall effective december year transfer shall irrevocable pursuant term split dollar life insurance agreement designate compensation committee term condition set compensation committee election participant transfer amount income deferral account estate preservation plan participant shall deemed waive irrevocably right benefit plan respect amount transfer addition term set forth paragraph amount participant income deferral account transfer estate preservation plan order satisfy prior obligation participant connection estate preservation plan transfer shall solely direction compensation committee determination compensation committee transfer necessary shall effect term condition voluntary transfer paragraph determine committee transfer necessary participant income deferral account shall reduce requisite december year direct compensation committee determination compensation committee subsequent transfer amount estate preservation plan participant shall deem waive irrevocably right benefit plan respect amount transfer deduction distribution company deduct distribution amount require withhold income social security tax purpose withholding pro rata basis investment company deduct amount participant owe company reason beneficiary designation participant designate beneficiary receive value hisher income deferral account death beneficiary predecease participant beneficiary name designate beneficiary participant balance case distribute participant estate beneficiary designation revise time submit beneficiary designation form extra compensation service amendment committee amend plan time amendment shall consent participant materially adversely affect right obligation respect defer award theretofore miscellaneous company fund obligation create participant participation plan company make anunsecure promise pay obligation general corporate asset apply obligation active retired participant quarter calendar year statement send active participant participate plan retiree deferral account statement include previously deferral election beneficiary designation report retiree provide deferred payout balance plus interest defer andor installment election beneficiary designation plan shall administer extra compensation services department corporate headquarters company question regard administration plan address election defer andor pay installment consultation participant tax andor financial advisor text document document typeexo sequence filenameyexvwotxt descriptionletter agreement text exhibit june ralph larsen johnson johnson plaza new brunswick postemployment arrangement dear ralph november meet compensation committee board director discuss matter relate management succession transition leadership johnson johnson company meeting agree remain company april exchange certain arrangement available follow employment company include reimbursement office space furnishing equipment secretarial support access company aircraft meeting compensation committee june compensation committee determine good interest party clarify well define document arrangement follow ralph larsen serve chairman chief executive officer johnson johnson company april continue continue provide transition management advice william weldon current chairman chief executive officer request weldon compensation committee recognize base leadership company dedication credo value recognize expertise corporate management larsen serve retirement ambassador goodwill johnson johnson company larsen agree follow larsen agree period year follow retirement company request chief executive officer company participate external activity event benefit company larsen agree provide day year company subject reasonable availability participation external activity event larsen willing participate external activity event request chief executive officer company fee reimbursement cost expense wife consideration larsen dedicated service company continue visibility chairman board future role ambassador goodwill johnson johnson agreement provide service year behalf chief executive officer allof shall serve benefit company shareowner follow arrangement shall provide larsen benefit furnish office company pay staff furnish office larsen location determine larsen office arrangement include appropriate secretarial support computer telecommunication equipment support service office relate arrangement commensurate larsen position chairman board remain place duration life company aircraft larsen retirement duration life larsen entitle hour fly time year company aircraft own lease include helicopter hour determine base actual flying time larsen board aircraft larsen priority access company aircraft specific aircraft priority access mean larsen access company aircraft follow individual hold position list annex hereto shall priority access company aircraft director officer employee company position list annex modify mutual agreement chief executive officer larsen reflect change organizational structure larsen provide company reasonable advance notice request use company aircraft larsen accompany family member friend company aircraft taxis arise use company aircraft responsibility larsen provision action take agreement shall affect way larsen right company compensation employee benefit pension welfare plan program agreement unconditional irrevocable shall remain force effect regardless merger change control ownership sale substantially asset company change modification provision hereof shall bind writing sign larsen duly authorize representative board director company forego meet approval kindly sign acknowledge agreement term letter truly william weldon arnold langbo william weldon arnold langbo chairman chief executive officer chairman compensation committee accept agree ralph larsen ralph larsen text document document typeexp sequence filenameyexvwptxt descriptionconsulting agreement text exhibit consulting agreement agreement judah folkman individual business address child hospital hunnewell longwood avenue boston hereinafter call consultant johnson johnson business address johnson johnson plaza new brunswick hereinafter call jjwitnesseth desire engage consultant professional service consultant desire render professional service consultant represent obligation party interfere render professional service hereinafter define desire engage consultant professional service year period january december subject renewal consent party consideration premise mutual promise covenant contain party hereto agree follow offer engage consultant accept engagement consultant professional service follow advise attendance participation scientific advisory committee meeting consideration consultant acceptance consulting agreement performance professional service specifically set forth paragraph hereof shall pay consultant fee thousand dollar scientific advisory committee meeting attend start date set addition agree reimburse consultant reasonable outofpocket include jjauthorized travel expense incur provide consulting service hereunder airline expense generally reimburse business class level receipt shall require individual expense exceed order carry consulting service set forth necessary disclose provide consultant certain technical economic scientific andor business information relate research development activity interest affiliate hereinafter collectively refer information consider proprietary additionally certain technical economic scientific andor business information develop consultant course service provide hereunder information include term information consultant agree information strict confidence disclose use information purpose performance service contemplate prior write consent invention patentable improvement idea information conceive connection performance service hereunder shall exclusive property consultant charge shall execute acknowledge deliver paper include assignment application patent necessary enable publish protect say invention improvement idea patent country vest title say patent invention improvement idea nominee successor assign shall render assistance require patent office proceeding litigation involve say invention improvement idea information copyrightable work create consultant connection performance service contemplate agreement shall consider work hire publish unpublished right shall property employer author owner copyright work consultant charge reasonable payment time involve event service contain agreement shall terminate expense shall duly execute acknowledge deliver paper include assignment application copyright registration renewal necessary enable publish protect say work copyright country vest title say work nominee successor assign shall render assistance require proceeding litigation involve right say work reserve right time write notice consultant terminate agreement event shall obligate pay consultant service provide prior termination consultant agrees promptly inform occurrence affect ability consult hereunder include similar agreement pharmaceutical company research organization consultant represent obligation agreement party prevent carry duty obligation agreement consultant agree originate use employee publicity news release public announcement write oral public press relate consulting agreement amendment hereto performance hereunder prior write consent consultant agree matter arise consulting agreement shall interpret law state new jersey united states america venue decide dispute hereunder shall state new jersey consultant understand agree relationship hereunder independent contractor employee agent entitle participate benefit privilege available employee provide terminate pursuant paragraph term agreement shall year date set forth december agreement shall renewable successive year period mutual write consent party notwithstanding termination agreement right obligation recite paragraph shall continue witness whereof party hereto cause agreement duly execute day year sign date december text document document typeex sequence filenameyexvtxt descriptionstatement computation ratio earning text exhibit johnson johnson subsidiaries statement computation ratio earning fix charge dollar million table caption fiscal year end december december december january january determination earning earning provision taxis income fix charge total earning define fix charge rent interest fix charge capitalize interest total fix charge ratio earning fix charge table ratio earning fix charge represent historical ratio johnson johnson calculate total enterprise basis ratio compute dividing sum earning provision taxis fix charge exclude capitalize interest fix charge fix charge represent interest include capitalize interest amortization debt discount expense interest factor rental consist appropriate interest factor operating lease text document document typeex sequence filenameyexvtxt descriptionpage annual report shareholder text exhibit management discussion analysis result operation financial condition overview record sale billion exceed sale billion mark year consecutive positive sale growth growth lead strong performance pharmaceutical medical device diagnostic segment balance sheet remain strong cash generate operation billion cash dividend share pay shareholder increase represent consecutive year cash dividend increase company continue company triple credit rating organization management objective company objective achieve superior level capital efficient profitable growth accomplish company management operate business consistent certain strategic principle prove successful time end company participate growth area human health care commit attain leadership position growth segment development innovative product service approximately billion sale invest research development recognize importance ongoing development new differentiate product service company system management operate decentralize basis operating company locate country company view management philosophy asset fundamental success broadly base business foster entrepreneurial spirit combine extensive resource large organization ability react quickly local market change challenge business manage long term order sustain leadership position achieve growth provide endure source value shareholder unify management team company dedicated employee achieve objective johnson johnson credo credo provide common set value serve constant reminder company responsibility customer employee communitie shareholder company believe basic principle overall mission improve quality life people enable johnson johnson continue leader health care industry result corporate governance issue certain company government lawmaker enact sarbanesoxley act protect investor improve accuracy reliability corporate disclosure light legislation company establish document formal process exist internal control like annual certification compliance management policy business conduct company continue evaluate enhance internal control process additionally company continue maintain strong ethical environment johnson johnson credo overall guidedescription business company approximately employee worldwide engage manufacture sale broad range product health care field company sell product virtually country world company primary interest historically currently product relate human health wellbee company organize principle decentralize management executive committee johnson johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie domestic international company span consumer pharmaceutical medical device diagnostic segment international subsidiary exception manage citizen country locate product line company compete company large small locate united states america abroad competition strong line regard number size compete company involve competition research involve development improvement new exist product process particularly significant result time time product process obsolescence development new improve product important company success area business competitive environment require substantial investment continue research multiple sale force addition win retention customer acceptance company consumer product involve heavy expenditure advertising promotion description segment consumer consumer segment principal product personal care include nonprescription drug adult skin hair care product baby care product oral care product aid product woman health product nutritional product product market principally general public distribute wholesaler directly independent chain retail outlet world major brand skin hair care line product include neutrogena roc aveeno clean clear johnson piz buin sundown sun care product shower shower personal care product major brand overthecounter line product include broad family tylenol acetaminophen product adult child motrin analgesic product imodium mylanta pepcid acid controller johnson johnson merck consumer pharmaceutical major brand woman health care line product include carefree stayfree tampons monistat major brand baby care line product include johnson baby line product penaten natusan baby care product major aid product include bandaid brand adhesive bandage compeed major oral care product include reach brand toothbrush major product nutritional product line include splenda noncaloric sugar substitute viactiv calcium chew benecol food product pharmaceutical pharmaceutical segment principal worldwide franchises antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology field product distribute directly wholesaler health care professional use prescription general public prescription drug antifungal field include nizoral ketoconazole sporanox itraconazole terazol terconazole daktarintm miconazole nitrate antifungal product prescription drug antiinfective field include floxin ofloxacin levaquin levofloxacin prescription drug cardiovascular field include retavase reteplase recombinant biologic cardiology care product treatment acute myocardial infarction improve blood flow heart reopro abciximab treatment acute cardiac disease prescription drug contraceptive field include ortho evra norelgestrominethinyl estradiol transdermal system orthonovum norethindroneethinyl estradiol tricilest norgestimateethinyl estradiol sell ortho tricyclen group oral contraceptive prescription drug dermatology field include retina micro tretinoin dermatological cream acne prescription drug gastrointestinal field include aciphex rabeprazole sodium proton pump inhibitor treat erosive gastroesophageal reflux disease gerd duodenal ulcer whichthe company derive service revenue product promote eisai imodium loperamide hcl antidiarrheal motilium domperidone gastrointestinal mobilizer remicade infliximab novel monoclonal antibody treatment certain crohn disease patient remicade indicate treatment rheumatoid arthritis prescription drug hematology field include procrit epoetin alfa sell outside eprex biotechnology derive version human hormone erythropoietin stimulate red blood cell production prescription drug immunology field include orthoclone okt muromonabcd reverse rejection kidney heart liver transplant prescription drug neurology field include topamax topiramate reminyl galantamine stugeron cinnarizine prescription drug oncology field include doxil doxorubicin anticancer treatment ergamisol levamisole hydrochloride colon cancer drug leustatin cladribine hairy cell leukemia prescription drug psychotropic central nervous system field include antipsychotic drug risperdal risperidone haldol haloperidol concerta methylphenidate attention deficithyperactivity disorder prescription drug pain management field include duragesic fentanyl transdermal system sell abroad durogesic transdermal patch chronic pain ultracettm tramadol hydrochloride analgesic moderate moderately severe pain prescription drug urology field include ditropan oxybutynin treatment overactive bladder medical device diagnostic medical device diagnostic segment include broad range product direction health care professional product include ethicon wound care surgical sport medicine woman health product ethicon endosurgery minimally invasive surgical product cordis circulatory disease management product lifescan blood glucose monitoring product orthoclinical diagnostic professional diagnostic product depuy orthopaedic joint reconstruction spinal product vistakon disposable contact lense product principally professional field physician nurse therapist hospital diagnostic laboratory clinic acquisition medical device diagnostic segment recent year integral ongoing process transform medical supply business serve range high technology medical specialty operating result sale worldwide sale increase billion compare increase sale large distributor amerisourcebergen corp mckesson hboc cardinal distribution account respectively total revenue exclude impact foreign currency worldwide sale increase price increase account approximately growth respectively sale domestic company billion billion billion represent increase sale international company billion billion billion represent increase exclude impact foreign currency fluctuation past year sale international company increase year annual compound growth rate sale exclude impact foreign currency fluctuation annual compound growth rate sale year period geographic area world post operational gain exclude effect exchange rate fluctuation dollar foreign currency sale increase europe western hemisphere exclude asiapacific africa region include impact currency fluctuation sale increase europe asiapacific africa decrease western hemisphere exclude company achieve annual compound growth rate worldwide sale year period domestic sale grow rate international sale grow rate exclude impact foreign currency fluctuation annual compound growth rate year period consumer segment sale billion increase increase consumer segment sale prior year operational growth currency negatively impact sale growth domestic sale increase international sale gain localcurrency offset negative currency impact result total international growth consumer sale achieve strong growth skin care product neutrogena clean clear aveeno bandaid wound care product mcneil nutritional splenda sweetener product viactiv calcium chew consumer segment sale billion increase domestic sale increase international sale gain local currency offset negative currency impact result total growth consumer segment sale billion increase domestic sale increase international sale gain local currency offset negative currency impact result total decrease pharmaceutical segment sale billion increase include growth domestic sale total growth international sale include positive effect currency increase pharmaceutical segment sale prior year operational increase currency positively impact sale growth sale growth reflect strong performance procriteprex treatment anemia remicade treatment rheumatoid arthritis crohn disease risperdal antipsychotic medication duragesic transdermal patch chronic pain topamax antiepileptic medication sale procriteprex account total company revenue johnson johnson markets prescription drug world sale generate outside united states thirtythree drug sell company sale excess million excess million rate growth sale procrit eprex slow half result new competition procrit sale growth affect rare report pure red cell aplasia prca chronic renal failure crf patient administer eprex subcutaneously company ongoing investigation prca crf patient indicate occurrence prca continue rare second quarter company complete acquisition tibotecvirco approximately million tibotecvirco privatelyheld biopharmaceutical company focus develop antiviral treatment promising compound development treatment infectious disease include hiv fourth quarter company receive food drug administration fda approval levaquin levofloxacin additional indication treatment nosocomial pneumonia second common hospitalacquire infection company file new drug application fda include topamax topiramate prevention migraine headache adult use monotherapy treatment epilepsy currently approve adjunctive treatment levaquin fiveday treatment communityacquire pneumonia risperdal risperidone adjunctive monotherapy treatment bipolar disorder fourth quarter company announce definitive agreement acquire orapharma inc specialty pharmaceutical company focus development commercialization unique therapeutic oral health care product acquisition provide entry oral health professional marketplace provide synergistic line prevention treatment product maintain periodontal health transaction value approximately million net cash close quarter pharmaceutical segment sale billion total increase include growth domestic sale operationally international sale increase partially offset negative currency impact result total growth pharmaceutical segment sale billion increase include growth domestic sale operationally international sale increase offset negative currency impact result total decrease sale sale growth partially offset restrict access propulsid number market world worldwide sale billion medical device diagnostic segment represent increase currency impact sale growth total increase operational sale increase prior year domestic sale international sale increase prior year strong sale growth achieve major franchise segment cordis circulatory disease management product depuy orthopaedicjoint reconstruction spinal product ethicon wound care surgical sport medicine woman health product lifescan blood glucose monitoring product ethicon endosurgery minimally invasive surgical product orthoclinical diagnostic professional diagnostic product vistakon disposable contact lense quarter company announce final result sirius landmark study cyphertm sirolimuselute stent drugelute coronary stent kind recommend fda approval clinical result cyphertm stent indicate significant reduction instent restenosis revascularization rate compare bare metal stent finding confirm stent continue excellent performance significantly reduce reblockage coronary artery patient coronary artery disease additionally july department health human service hhs decision provide accelerate incremental reimbursement hospital technology commence april newly establish diagnostic relate group drg order ensure access technology patient rapidly possible hhs take unprecedented step assign new drg prior fda approval october circulatory system device panel advisory panel vote favor fda approval recommend condition company drugelute coronary stent company continue work fda ongoing review product approval fourth quarter fda orthopaedic rehabilitation device panel unanimously recommend favor fda approval condition independencetm ibottm mobility system ibottm mobility system unique device offer benefit individual mobilityrelate disability device navigate difficult terrain climb stair ramp balance stand height wheel december ethicon receive fda clearance market vicryl plus antibacterial suture suture design antibacterial agent design reduce bacterial colonization suture vicryl plus help reduce risk complication associate surgery worldwide sale billion medical device diagnostic segment represent total increase domestic sale international sale increase sale gain local currency offset negative currency impact worldwide sale billion medical device diagnostic segment represent total increase consist gain local currency reduce strength dollar domestic sale international sale increase sale gain local currency offset negative currency impact gross profit gross profit margin improvement gross profit margin improvement gross profit margin gross profit margin improvement improvement gross profit margin past year primarily result continue improvement mix business successful ongoing cost control effort sell general administrative expense consolidated sell general administrative expense increase respectively sell general administrative expense percent sale respectively result implementation emerge issue task force eitf issue account consideration give vendor customer reseller vendor product company reclassify million million respectively sell general administrative expense reduction sale reclassify million million expense respectively sell general administrative expense cost product sell advertising expense comprise television radio print medium internet advertising billion billion billion research expense research activity represent significant company businessthese expenditure relate development new product improvement exist product technical support product compliance governmental regulation protection consumer patient worldwide cost research activity exclude inprocess research development charge follow table caption million dollar research expense percent increase prior year percent sale table research expense percent sale pharmaceutical segment average consumer medical device diagnostic segment respectively significant research activity continue pharmaceutical segment spending increase billion represent compound annual growth rate approximately fiveyear period johnson johnson pharmaceutical research development llc know janssen research foundation johnson pharmaceutical research institute primary worldwide pharmaceutical research organization additional research conduct centocor alza corporation alza tibotecvirco collaboration james black foundation london england inprocess research development second quarter company record inprocess research development iprd charge million aftertax million tax iprd generally tax deductible relate acquisition acquisition include tibotecvirco privatelyheld biopharmaceutical company focus develop antiviral treatment obtech medical privatelyheld company market adjustable gastric band treatment morbid obesity fourth quarter iprd charge million aftertax million tax iprd generally tax deductible incur result acquisition inverness medical technology supplier lifescan electrochemical product blood glucose monitoring follow spinoff nondiabetes business terame early stage medical device company develop endovascular stentgraft system minimally invasive treatment abdominal aortic aneurysm peripheral occlusive disease company iprd charge million aftertax million tax iprd generally tax deductible relate acquisition atrionix inc development stage company primary product pulmonary ablation catheter treatment atrial fibrillation crescendo company form alza purpose select develop commercialize human pharmaceutical product interest income expense interest income decrease primarily decline interest rate cash expend stock repurchase program average yield investment basis point average yield interest expense compare remain relatively constant significant change average debt balance income expense net income expense include gain loss relate sale writedown certain equity securities johnson johnson development corporation loss disposal fix asset currency gain loss minority interest litigation settlement expense royalty income additionally income expense include gain sale ortho pref product line impact amgen arbitration settlementon october arbitrator chicago deny effort amgen inc terminate license agreement ortho biotech obtain exclusive right amgendevelope erythropoietin epo sell procriteprex indication outside kidney dialysis amgen file suit claim ortho biotech breach license right improperly make sale epo amgen exclusive dialysis market decision arbitrator find sale market amgen retain exclusive right warrant extraordinary remedy terminate contract instead find amgen adequately compensate monetary damage arbitrator award million damage record quarter arbitration fourth party january arbitrator rule amgen prevail party arbitration entitling award reasonable attorney fee cost amgen submit application fee cost company expense million fourth quarter connection outstanding claim addition item indicate income expense include cost relate merger alza million amortization expense approximately million long require financial accounting standard board fasb standard goodwill intangible asset sfas addition item indicate income expense include favorable adjustment cost associate global manufacturing restructuring charge gain sale product line earning provision taxis income consolidated earning provision taxis income increase respectively exclude iprd merger charge note previous section increase respectively increase primarily volume growth improve gross profit margin efficiency spending sell marketing administrative expense operate profit segment follow table caption percent sale million dollar consumer pharmaceutical med devices diag segment total expense allocate segment earning taxis income table increase expense allocate segment primarily decline interest income discuss interest income expense section consumer segment operating profit increase prior year reflect operate profit percent sale improvement improvement primarily leverage selling promotion administrative expense offset increase expenditure advertising additionally consumer segment operating profit improve amortization expense long require sfas pharmaceutical segment operating profit increase reflect operate profit percent sale improvement pharmaceutical segment operating profit negatively impact cost amgen arbitration settlement million damage million legal fee iprd related tibotecvirco acquisition offset gain sale ortho prefest product line impact sfas operating profit percent sale pharmaceutical segment pharmaceutical segment operating profit include effect leverage marketing expense pharmaceutical operating profitinclude expense relate merger alza medical device diagnostic segment operating profit increase reflect operate profit percent sale improvement nonamortization sfas account improvement remain margin improvement prior year achieve despite investment spending support cordis product line operating profit include iprd associate acquisition obtech medical inverness medical technology terame provision taxis income worldwide effective income tax rate increase effective tax rate year primarily increase income subject tax company nondeductible iprd charge refer footnote financial statement additional information net income earning share worldwide net earning billion reflect increase worldwide net earning share equal share increase net earning share exclude impact iprd impact iprd merger cost worldwide net earning billion net earning share represent increase respectively impact nonamortization sfas increase net earning earning share approximately worldwide net earning achieve year annual growth rate earning share grow rate exclude impact accounting change iprd worldwide net earning achieve year annual growth rate earning share grow rate year annual compound growth rate net earning earning share respectively exclude impact iprd merger cost worldwide net earning achieve year annual growth rate earning share grow rate worldwide net earning billion reflect increase worldwide net earning share equal share increase net earning share exclude impact iprd merger cost iprd net favorable adjustment cost associate global manufacturing restructuring charge worldwide net earning billion net earning share represent increase respectively worldwide net earning billion reflect increase worldwide net earning share equal share increase net earning share exclude impact iprd net favorable adjustment cost associate global manufacturing restructure charge merger cost worldwide net earning billion net earning share represent increase respectively cash flow liquidity cash generate operation select borrowing provide major source fund growth business include work capital capital expenditure acquisition share repurchase dividend debt repayment cash current marketable security billion end compare billion end cash generate operation amount billion cash generate operation billion decrease primarily fund pension plan approximately million net current tax benefit change time salary increase bonus pay employee december february change enact result finalize order align compensation performance result change increase approximately million cash flow operating activity payment bonus capital expenditure capital expenditure increase billion increase billion increase primarily expansion manufacturing facility support new exist product investment support research investment information system business segmentsshare repurchase dividend february company announce stock repurchase program billion time limit program program complete august million share repurchase aggregate price billion addition stock repurchase program company annual program repurchase share use employee stock employee incentive plan company increase cash dividend consecutive year cash dividend pay share compare dividend share share dividend distribute follow table caption quarter second quarter quarter fourth quarter total table january board director declare regular cash dividend share pay march shareholders record february company expect continue practice pay regular cash dividend contractual obligation commitment company longterm contractual obligation primarily lease debt obligation satisfy obligation company intend use cash operation follow table summarize company contractual obligation aggregate maturity december note detail table caption operate debt million dollar lease obligation table financial position capital resource total asset return total asset increase billion billion consolidated asset yearend medical device diagnostic account pharmaceutical segment asset consumer segment asset general corporate asset yearend consolidated asset identifiable medical device diagnostic pharmaceutical segment respectively consumer segment general corporate asset respectively net intangible asset increase represent total asset yearend net property plant equipment increase billion represent total asset yearend shareholder equity share end compare yearend decrease decrease primarily billion stock repurchase program complete finance market risk company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value exist foreign currency asset liability hedge future foreign currency product cost gain loss contract offset primarily effect foreign exchange rate change underlie transaction appreciation dollarfrom december market rate increase unrealized value company forward contract million conversely depreciation dollar december market rate decrease unrealized value company forward contract million scenario gain loss forward contract offset effect foreign exchange rate change underlie transaction company enter currency swap contract manage company exposure change currency exchange rate hedge foreign currency denominate asset liability impact change interest rate company interest rate sensitive financial instrument immaterial company enter financial instrument trade speculative purpose company policy enter contract party equivalent credit rating counterpartie contract major financial institution company significant exposure counterparty management believe risk loss remote total unused credit available company approximate billion include billion credit commitment billion uncommitted line bank worldwide expire company shelf registration file security exchange commission enable company issue billion unsecured debt security warrant purchase debt security medium term note mtn program mtn issue december company billion remain shelf registration company continue company triple credit rating total borrowing end billion billion respectively net cash cash current marketable security net debt billion net cash cash current marketable security net debt billion total debt represent total capital shareholder equity total debt total capital period end december material cash commitment summary borrowing find note company believe operation comply material respect applicable environmental law regulation company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state law relief seek cost past future remediation feasible predict determine outcome proceeding opinion company proceeding material adverse effect result operation cash flow financial position company matter critical accounting policy estimate management discussion analysis result operation financial condition base company consolidated financial statement prepare accordance accounting principle generally accept preparation financial statement require management estimate assumption affect amount report revenue expense asset liability relate disclosure actual result differ estimate company significant accounting policy describe note company believe understand certain key accounting policy estimate essential achieve insight company operating result financial condition key accounting policy estimate include revenue recognition accounting income taxis legal self insurance contingency valuation long live asset assumption determine amount record pension employee benefit plan account stock option revenue recognition company recognize revenue product sale good ship deliver depend title risk pass customer provision certain rebate sale incentive trade promotion coupon product return discount customer provide reduction determine sale period relate sale record provision large medicaid rebate provision base estimate derive current program requirement historical experience company recognize service revenue receive copromotion certain product yearend december revenue total revenue include product salesincome taxis income taxis record base amount refundable payable current year include result difference gaap account tax reporting record defer tax asset liability company record defer tax asset liability base current tax regulation rate change tax law rate affect defer tax asset liability record future management believe change estimate material effect company result operation cash flow financial position company intend continue reinv undistributed international earning expand international operation tax expense record cover repatriation undistribute earning december december cumulative undistribute international earning approximately billion billion respectively legal self insurance contingency company record accrual contingency include legal proceeding product liability case arise normal course business accrual base management judgment probability loss opinion legal counsel applicable actuarially determined estimate additionally company record insurance receivable amount party insurer base probability recovery appropriate reserve receivables record estimate amount collect party insurer long live intangible asset company assess change economic condition strategic priority make assumption estimate future cash flow evaluate value company fix asset goodwill noncurrent asset assumption estimate change time necessary company record impairment charge employee benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide plan require assumption discount rate expect return plan asset expect salary increase health care cost trend rate note detail rate effect change rate company result operation stock option company elect use accounting principle board opinion accounting stock issue employee apb require compensation cost relate stock option record net income option grant stock option plan exercise price equal market value underlie common stock grant date statement financial accounting standard sfas accounting stockbase compensation transition disclosure amendment fasb statement require pro forma disclosure net income earning share determine fair value method accounting stock option apply measure compensation cost note information stock option new accounting standard june fasb issue sfas accounting asset retirement obligation company adopt standard effective fiscal year begin june expect material impact company result operation cash flow financial position august fasb issue sfas accounting impairment disposal longlive asset effective quarter company adoption sfas material effect company result operation cash flow financial position june fasb issue sfas accounting cost associate exit disposal activity effective exit disposal activity initiate december company adopt sfas quarter expect material effect company result operation cash flow financial positionon november fasb issue fasb interpretation fin guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness interpretation fasb statement rescission fasb interpretation fin clarifie requirement fasb statement accounting contingency relate guarantor accounting disclosure issuance certain type guarantee disclosure requirement fin effective financial statement interim annual period end december adopt company disclosure require yearend provision initial recognition measurement effective prospective basis guarantee issue modify december irrespective guarantor yearend fin require issuance guarantee entity recognize liability fair value obligation assume guarantee company adoption fin expect material effect company result operation cash flow financial position january fasb issue fin consolidation variable interest entity interpretation arb address consolidation variable interest entity fin expand criterion consideration determine variable interest entity consolidated business entity require exist unconsolidated variable interest entity include limited special purpose entity spe consolidate primary beneficiary entity effectively disperse risk party involve interpretation apply immediately variable interest entity create january variable interest entity enterprise obtain interest date apply fiscal year interim period begin june variable interest entity enterprise hold variable interest acquire february adoption fin expect material effect company result operation cash flow financial position change price inflation johnson johnson aware product set decade policymaker consumer business express concern rise cost health care response concern johnson johnson longstanding policy pricing product responsibly period united states weight average compound annual growth rate johnson johnson price increase health care product prescription overthecounter drug hospital professional product consumer price index cpi period inflation rate moderate part world continue effect worldwide economy consequently way company operate face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase common stock market price company common stock list new york stock exchange symbol jnj composite market price range johnson johnson common stock table caption high low high low quarter second quarter quarter fourth quarter yearend close table subsequent event february johnson johnson announce sign definitive agreement scios inc biopharmaceutical company market product cardiovascular disease research project focus autoimmune disease company acquire scios cash stock exchange term agreement scio shareholder receive outstanding scios share value transaction anticipate closing date expect approximately billion net cashanticipate acquire base scio approximately million fully dilute share outstanding board directors johnson johnson scios give approval transaction subject clearance hartscottrodino antitrust improvement act transaction subject approval shareholder scio customary closing condition scio biopharmaceutical company develop novel treatment cardiovascular inflammatory disease company diseasebase technology platform integrate expertise protein biology computational medicinal chemistry identify novel target rationally design small molecule compound large market unmet medical need scio product natrecor novel agent approve congestive heart failure chf decade natrecor recombinant form naturally occur protein secrete heart body response chf drug significant advantage exist therapy chf single common cause hospitalization united states patient principal focus scio research development program small molecule inhibitor include potential new treatment pain inflammatory disease include advanced kinase inhibitor program transaction expect close second quarter company anticipate iprd charge approximately million incur connection acquisition cautionary factor affect future result annual report contain forwardlooke statement forwardlooke statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word like plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forward look statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement furthermore company assume obligation update forwardlooke statement result new information future event development company report year end december file march contain exhibit discussion factor cause actual result differ expectation prior file investor reference company report fiscal year end december company note factor permit private security litigation reform act consolidated balance sheet johnson johnson subsidiaries december december dollar million share share datum note table caption asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis income note prepay expense receivables total current asset marketable security noncurrent note property plant equipment net note intangible asset net note defer taxis income note asset note total asset liabilitie shareholder equity current liability loan note payable note account payable accrue liability accrue salary wage commission taxis income total current liability longterm debt note defer tax liability note employee relate obligation note liabilitie shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share note receivable employee stock ownership plan note accumulate comprehensive income note retain earning common stock hold treasury cost note total shareholder equity total liability shareholder equity table note consolidated financial statement consolidate statement earning johnson johnson subsidiarie dollar million share figure note table caption sale customer cost product sell gross profit selling market andadministrative expense research expense purchase inprocess research development note interest income interest expense net portion capitalize note income expense net earning provision taxis income provision taxis income note net earning basic net earning share note dilute net earning share note table note consolidated financial statement consolidate statement equity johnson johnson subsidiaries dollar million note table caption note rec employee compre stock owner hensive retain ship plan total income earning esop balance jan net earning cash dividend pay employee stock compensation stock option plan conver subordinate debenture repurchase common stock business combination comprehensive income net tax curncy translation adj unrealize gainslosses security pension liab adj reclassification adj total comprehensive income note receivable esop bal dec net earning cash dividend pay employee stock compensation stock option plan conver subordinate debenture repurchase common stock business combination comprehensive income net tax curncy translation adj unrealize gainslosse security gainslosse derivative hedge reclassification adj total comprehensive income note receivable esop bal dec net earning cash dividend pay employee stock compensation stock option plan conver subordinate debenture repurchase common stock comprehensive income net tax curncy translation adj unrealize gainslosses security pension liab adj gainslosses derivative hedge reclassification adj total comprehensive income note receivable esop bal dec table note consolidated financial statement consolidate statement equity johnson johnson subsidiaries dollar million note table caption accumul common compre stock treasury hensive issue stock income balance jan net earning cash dividend pay employee stock compensation stock option plan conver subordinate debenture repurchase common stock business combination comprehensive income net tax curncy translation adj unrealize gainslosses security pension liab adj reclassification adj total comprehensive income note receivable esop bal dec net earning cash dividend pay employee stock compensation stock option plan conver subordinate debenture repurchase common stock business combination comprehensive income net tax curncy translation adj unrealize gainslosse security gainslosse derivative hedge reclassification adj total comprehensive income note receivable esop bal dec net earning cash dividend pay employee stock compensation stock option plan conver subordinate debenture repurchase common stock comprehensive income net tax curncy translation adj unrealize gainslosses security pension liab adj gainslosses derivative hedge reclassification adj total comprehensive income note receivable esop bal dec table note consolidated financial statement consolidate statement cash flow johnson johnson subsidiaries dollar million note table caption cash flow operating activity net earning adjustment reconcile net earning cash flow depreciation amortization property intangible purchase inprocess research development defer tax provision account receivable reserve change asset liability net effect acquisition business increase account receivable increase decrease inventory increase account payable accrue liability increase decrease current noncurrent asset increase current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition business net cash acquire note purchase investment sale investment net cash invest activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent decrease increase cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition business fair value asset acquire fair value liability assume treasury stock issue fair value net cash pay acquisition table note consolidated financial statement note consolidated financial statement summary significant accounting principle principle consolidation financial statement include account johnson johnson subsidiaries intercompany account transaction eliminate new accounting pronouncementsin june financial accounting standard board fasb issue statement financial accounting standard sfas accounting asset retirement obligation company adopt standard effective fiscal year begin june expect material impact company result operation cash flow financial position august fasb issue sfas accounting impairment disposal longlive asset effective quarter company adoption sfas material effect company result operation cash flow financial position june fasb issue sfas accounting cost associate exit disposal activity effective exit disposal activity initiate december company adoption sfas quarter expect material effect company result operation cash flow financial position november fasb issue fasb interpretation fin guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness interpretation fasb statement rescission fasb interpretation fin clarifie requirement fasb statement accounting contingency relate guarantor accounting disclosure issuance certain type guarantee disclosure requirement fin effective financial statement interim annual period end december disclosure provision implement disclosure require yearend provision initial recognition measurement effective prospective basis guarantee issue modify december irrespective guarantor yearend fin require issuance guarantee entity recognize liability fair value obligation assume guarantee company adoption fin expect material effect company result operation cash flow financial position january fasb issue fin consolidation variable interest entity interpretation arb address consolidation variable interest entity fin expand criterion consideration determine variable interest entity consolidated business entity require exist unconsolidated variable interest entity include limited special purpose entity spe consolidate primary beneficiary entity effectively disperse risk party involve interpretation apply immediately variable interest entity create january variable interest entity enterprise obtain interest date apply fiscal year interim period begin june variable interest entity enterprise hold variable interest acquire february adoption fin expect material effect company result operation cash flow financial position cash equivalent company consider security maturity month purchase cash equivalent investment shortterm marketable security carry cost approximate fair value longterm debt security company ability intent hold maturity carry amortize cost approximate fair value investment classified availableforsale carry estimate fair value unrealize gain loss record component accumulate comprehensive income management determine appropriate classification investment debt equity security time purchase reevaluate determination balance sheet date company periodically review investment nonmarketable equity security impairment adjust investment fair value decline market value deem temporary property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset building building equipment year land leasehold improvement year machinery equipment year company capitalize certain computer software development cost incurredin connection develop obtain computer software internal use capitalize software cost amortize estimate useful life software generally range year company review longlive asset assess recoverability undiscounted cash flow necessary charge impairment longlive asset record present value future cash flow carry value asset revenue recognition company recognize revenue product sale good ship deliver depend title risk pass customer provision certain rebate sale incentive trade promotion product return discount customer provide reduction determine sale period relate sale record sale incentive trade promotional allowance company adopt emerge issue task force eitf issue account consideration give vendor customer reseller vendor product effective december prior period restate reclassify sale incentive trade promotional allowance sell general administrative expense reduction sale cost sale sale reduce million million respectively cost product sell increase million million respectively ship handling shipping handling cost incur million million million respectively include sell marketing administrative expense revenue receive shipping handle immaterial period present inventory inventory state low cost market determine firstin firstout method intangible asset accordance sfas amortization record goodwill andor intangible asset deem indefinite life acquisition complete june effective begin fiscal year accordance sfas company discontinue amortization relate exist goodwill indefinite live intangible asset effect nonamortization goodwill intangible asset approximately million tax intangible asset finite useful life continue amortize useful life sfas require goodwill non amortizable intangible asset assess annually impairment require initial assessment complete june impairment determine initial impairment assessment update fourth quarter impairment determine future impairment test perform fourth quarter annually financial instrument effective january company adopt sfas accounting derivative instrument hedge activity amend sfas account certain derivative instrument certain hedging activity amendment fasb statement collectively refer sfas sfas require derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction depend type hedge transaction company use forward exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future intercompany product party purchase raw material denominate foreign currency company use currency swap manage currency risk primarily relate borrowing type derivative designate cash flow hedge additionally company use forward exchange contract offset exposure certain foreign currencyasset liabilitie forward exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability designation cash flow hedge date enter derivative contract inception derivative expect highly effective change fair value derivative designate cash flow hedge highly effective record accumulate comprehensive income underlie transaction affect earning reclassify earning account hedge transaction fair value forward exchange contract represent present value change forward exchange rate times notional derivative fair value currency swap contract determine discount present future cash flow currency exchange interest rate prevail market period currency exchange express result dollar current spot foreign currency exchange rate ongoing basis company assess derivative continue highly effective offset change cash flow hedge item derivative long expect highly effective hedge accounting discontinue hedge ineffectiveness include current period earning company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financial performance protect company cash flow adverse movement foreign exchange rate ensure appropriateness financial instrument manage enterprise risk associate financial institution product liability accrual product liability claim record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically additional information available receivables insurance recovery relate product liability relate claim record undiscounted time value money basis probable recovery realize research development research development expense expense incurred upfront milestone payment party connection research development collaboration expense incur point regulatory approval payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible net accumulate amortization advertising cost associate advertising expense year incur advertising expense worldwide comprise television radio print medium internet advertising billion billion billion income taxis company intend continue reinv undistributed international earning expand international operation tax expense record cover repatriation undistribute earning december december cumulative undistribute international earning approximately billion billion respectively defer income taxis recognize tax consequence temporary difference apply enact statutory tax rate applicable future year difference financial reporting tax basis exist asset liability net earning sharebasic earning share compute divide net income available common shareholder weight average number common share outstanding period dilute earning share reflect potential dilution occur security contract issue common stock exercise convert common stock stock option december company stockbase employee compensation plan describe note company account plan recognition measurement principle accounting principle board opinion accounting stock issue employee relate interpretation compensation cost record net income stock option option grant plan exercise price equal market value underlie common stock date grant require sfas accounting stockbase compensation transition disclosure amendment fasb statement follow table show estimate effect net income earning share company apply fair value recognition provision sfas accounting stockbase compensation stockbase employee compensation table caption dollar million share datum net income report compensation expense pro forma earning share basic report pro forma diluted report pro forma table determine fair value base method awards net tax risk uncertaintie preparation consolidated financial statement conformity accounting principle generally accept require management estimate assumption affect amount report actual result differ estimate annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year case fiscal year consist week reclassification certain prior year amount reclassify conform current year presentation stock split april board director declare stock split shareholder record close business issue additional share johnson johnson common stock june share hold record date share share datum period present financial statement adjust reflect stock split inventory end inventory comprise tablecaption dollar millions raw material supply good process finish good table property plant equipment end property plant equipment cost accumulate depreciation table caption dollar millions land land improvement building build equipment machinery equipment construction progress accumulate depreciation table company capitalize interest expense cost construction facility equipment interest expense capitalize million million million respectively depreciation expense include amortization capitalize interest billion billion billion respectively retirement disposal fix asset cost relate accumulate depreciation amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed adjust earning rental expense lease commitment rental space vehicle manufacture equipment office datum processing equipment operating lease amount approximately million million million approximate minimum rental payment require operating lease initial remain noncancelable lease term excess year december table caption dollar million total table commitment capital lease significant employee relate obligation end employee relate obligation table caption dollar millions pension benefit post retirement benefit post employment benefit defer compensation current benefit payable employee relate obligation table prepay employee relate obligation million include asset consolidate balance sheet borrowing component longterm debt follow table caption eff eff dollars millions rate rate zero coupon convertible subordinated debenture zero coupon convertible subordinated debenture debenture note debenture note eurodollar note note note industrial revenue bond principally international current portion table weight average effective rate represent dollar note issue japanese subsidiary convert fix rate yen note currency swap company access substantial source fund numerous bank worldwide total unused credit available company approximate billion include billion credit commitment billion uncommitted line bank worldwide expire interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material company shelf registration file security exchange commission enable company issue billion unsecured debt security warrant purchase debt security medium term note mtn program mtn issue december company billion remain shelf registration long term debt include convertible subordinated debenture issue alza prior merger johnson johnson july alza complete private offering zero coupon convertible subordinated debenture issue price principal maturity december outstanding debenture total principal maturity billion yield maturity annum compute semiannual bond equivalent basis periodic interest payment term debenturesholder entitle convert debenture approximately million share johnson johnson stock price share approximately share issue december voluntary conversion note holder option holder debenture repurchase company july purchase price equal issue price plus accrete original issue discount purchase date company option elect deliver johnson johnson common stock cash combination stock cash event repurchase debenture company option redeem debenture july issue price plus accrete original issue discount december december fair value base quote market value debenture million million respectively alza issue zero coupon convertible subordinated debenture price principal maturity december outstanding debenture total principal maturity million yield maturity annum compute semiannual bond equivalent basis periodic interest payment term debenture note holder entitle convert debenture approximately million share johnson johnson stock price share approximately million share johnson johnson stock issue december voluntary conversion note holder option holder debenture purchase company july july purchase price equal issue price plus accrete original issue discount purchase date december december fair value base quote market value debenture million million respectively shortterm borrowing current portion longterm debt amount billion end borrowing comprise billion commercial paper million local borrowing principally international subsidiary aggregate maturity longterm obligation commence table caption dollar millions table intangible asset end gross net amount intangible asset table caption dollar millions goodwill gross accumulate amortization goodwill net trademark nonamortizable gross accumulate amortization trademark nonamortizable net patent trademark gross accumulate amortization patent trademark net intangible gross accumulate amortization intangible net total intangible asset gross accumulate amortization total intangible asset net table goodwill december allocate segment business follow table caption med dev dollar million consumer pharm diag total goodwill net accumulate amortization december reclassification intangible net accumulate amortization acquisition translation goodwill december table weight average amortization period patent trademark intangible asset year year respectively amortization expense amortizable intangible asset fiscal year end december million pretax estimate amortization expense succeed year approximate million pretax year respectively income taxis provision taxis income consist table caption dollar millions currently payable tax international taxis defer taxis international taxis table comparison income tax expense federal statutory rate company effective tax rate follow table caption dollar millions international earning taxis income statutory taxis tax rate statutory puerto rico ireland operation research tax credit domestic state local international subsidiary exclude ireland iprd effective tax rate table company subsidiary operate puerto rico tax incentive grant expiring addition company subsidiary manufacture ireland incentive tax rate effective year temporary difference carry forwards follow table caption defer tax defer tax dollar million asset liab asset liab employee relate obligation depreciation nondeductible intangible international table table capitalize tax reserve liabilitie income report tax purpose miscellaneous international capitalize intangible miscellaneous total deferred income taxis table difference net defer tax income balance sheet net defer tax include taxis income balance sheet international currency translation translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year consolidate international subsidiary balance sheet currency effect record component accumulate comprehensive income equity account include result translate balance sheet asset liability current exchange rate locate highly inflationary economy reflect operating result analysis change foreign currency translation adjustment include note net currency transaction translation gain loss include expense aftertax loss million million million respectively common stock stock option plan stock compensation agreement december company stockbase compensation plan stock option plan company grant option employee issue share company common stock plus number share available previous year issue share issue plan expired terminate exercised share outstanding contract company employee stock option plan nonemployee director plan mitek cordis biosense gynecare centocor innovasive device alza inverness stock option plan stock option generally expire year date grant vest service period range year option grant current market price date grant share available stock option plan future grant base issue share year million share grant year year addition available share describe share available future grant plan million end summary status company stock option plan december december december change year end date present table caption weight option average share thousand outstanding exercise price balance january option grant option exercise option canceledforfeite balance december option grant option exercise option canceledforfeite balance december option grant option exercise option canceledforfeite balance december table include option issue replace inverness option outstanding grant prior acquisition year end december change timing grant stock compensation option employee december february change enact result finalize order align compensation performance timing grant follow fiscal average fair value option grant fair value estimate blackschole option pricing model base weighted average assumption table caption riskfree rate volatility expect life yrs yrs yrs dividend yield table follow table summarize stock option outstanding exercisable december table caption share thousand outstanding exercisable average average exercise average exercise exercise price range option lifea price option price table average contractual life remain year stock option exercisable december december option average exercise price option average exercise price respectively segment business geographic area information segment business geographic area accumulate comprehensive income component comprehensive incomeloss consist follow table caption total unrld gain accum gain pen loss cur loss liab deriv comp trans sec adj hedg incloss dollar million jan change dec change transitionadjustment net change hedging transaction net reclasse net earning net change dec change net change hedging transaction net reclasse net earning net change dec table total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million total comprehensive income include reclassification adjustment gain million associate tax expense million tax effect unrealize gainslosses equity security benefit million expense million expense million tax effect gainslosse derivative hedge benefit million expense million note additional information relate derivative hedge currency translation adjustment currently adjust income taxis relate permanent investment nonus subsidiary retirement pension plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily health care domestic retire employee dependent international employee cover government sponsor program cost company significant retirement plan benefit primarily base employee compensation year retirement number year service company objective fund domestic plan accumulate fund sufficient provide accrue benefit international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide certain country united states fund pension plan common practice funding provide economic benefit consequently company pension plan fund company fund retiree health care benefit advance right modify plan future net periodic benefit cost company define benefit retirement plan benefit plan include followingcomponent table caption retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost amortization net transition asset recognize actuarial gain curtailment settlement net periodic benefit cost table net periodic income cost attributable domestic retirement plan million million million follow table provide weightedaverage assumption develop net periodic benefit cost actuarial present value project benefit obligation table caption retirement plan benefit plan domestic benefit plan weight average discount rate expect longterm rate return plan asset rate increase compensation level international benefit plan weight average discount rate expect longterm rate return plan asset rate increase compensation level table health care cost trends united states project annual rate individual grade year effect change assume cost trend accumulate postretirement benefit obligation end million increase million decrease effect service interest cost component net periodic postretirement benefit cost million increase million decrease plan asset consist primarily list common stock nonus equity fix income investment fair value johnson johnson common stock plan asset million december follow table set forth change benefit obligation change plan asset yearend company define benefit retirement plan benefit plan table caption retirement plan benefit plan dollar million change benefit obligation benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial loss divestiture acquisition curtailment settlement total benefit pay effect exchange rate benefit obligation end year change plan asset plan asset fair value begin year table table actual return plan asset company contribution plan participant contribution divestiture benefit pay plan asset effect exchange rate plan asset fair value end year table amount recognize company balance sheet consist follow table caption retirement plan benefit plan dollar million plan asset project benefit obligation unrecognized actuarial loss gain unrecognize prior service cost unrecognized net transition asset total recognize consolidated balance sheet book reserve prepaid benefit intangible asset accumulate comprehensive income total recognize consolidated balance sheet table minimum pension liability adjustment require actuarial present value accumulate benefit abo exceed fair value plan asset accrue pension liability minimum pension liability adjustment million million respectively relate primarily plan outside plan accumulate benefit obligation excess plan asset consist follow table caption retirement plan benefit plan dollar million accumulate benefit obligation project benefit obligation plan asset fair value table marketable security table caption december real real est net ize ize fair cost gain loss value money market fund commercial paper time deposit government security obligation asset back security bank note corporate debt security total current marketable security government security asset back security bank note corporate debt security investment hold trust total noncurrent marketable security table table caption december real real est net ize ize fair cost gain loss value money market fund commercial paper time deposit government security obligation asset back security bank note corporate debt security total current marketable security government security asset back security bank note corporate debt security investment hold trust total noncurrent marketable security table current marketable security include billion billion classified cash equivalent balance sheet december december respectively financial instrument effective january company adopt sfas require derivative instrument record balance sheet fair value december balance defer net loss derivative include accumulate comprehensive income million aftertax additional information note company expect million reclassify earning month result transaction expect occur period ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative transaction party cause accumulate comprehensive income affect net earning maximum length time company hedge month year end december net impact hedge ineffectiveness company financial statement insignificant year end december company record net gain million tax income expense net category consolidate statement earning represent impact discontinuance cash flow hedge probable originally forecast transaction occur end originally specify time period refer note disclosure movement accumulate comprehensive income concentration credit risk company invest excess cash deposit major bank world high quality money market instrument refer note additional information company policy make investment commercial institution equivalent credit rating investment generally mature month company notincurre relate loss saving plan company voluntary saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan heshe eligible salary plan onethird company match pay company stock employee stock ownership plan esop establish esop company loan million esop trust purchase share company stock open market exchange company receive note balance record reduction shareholder equity total contribution plan million million million merger acquisition certain business acquire million cash liability assume million assume acquisition account purchase method accordingly result operation include accompany consolidated financial statement respective date acquisition acquisition include tibotecvirco privatelyheld biopharmaceutical company focus develop antiviral treatment micro typing systems inc manufacturer reagent supplier distribute instrument know idmicro type systemtm obtech medical privatelyheld company market adjustable gastric band treatment morbid obesity excess purchase price estimate fair value tangible asset acquire entity amount million allocate identifiable intangible goodwill addition approximately million identify value inprocess research development iprd associate tibotecvirco obtech medical acquisitions iprd charge related tibotecvirco million associate early stage hiv compound value iprd calculate assistance party appraiser cash flow projection discount risk inherent project probability success factor range discount rate iprd charge relate obtech medical million associate development current swedish adjustable gastric band sagb use united states development generation technology platform value iprd calculate assistance party appraiser cash flow projection discount risk inherent project probability success factor discount rate pro forma information provide impact acquisition material effect company result operation cash flow financial position june johnson johnson alza corporation alza complete merger company transaction account poolingofinterest alza approximately million share outstanding million fully dilute basis exchange approximately million share johnson johnson common stock dilute basis adjust stock option convertible debt number johnson johnson share issue total approximately million holder alza common stock receive share johnson johnson common stock value share alza researchbased pharmaceutical company lead drug delivery technology company apply delivery technology develop pharmaceutical product enhance therapeutic value johnson johnson affiliate portfolio world lead pharmaceutical company certain business acquire billion billion cash liability assume million share company common stock issue treasury value billion acquisition account purchase method accordingly result operationshave include accompany consolidated financial statement respective date acquisition acquisition include inverness medical technology supplier lifescan electrochemical product blood glucose monitoring follow spinoff nondiabetes business heartport company develop manufacture product invasive open chest minimally invasive heart operation include stop heart beat heart procedure terame inc earlystage medical device company develop endovascular stentgraft system minimally invasive treatment abdominal aortic aneurysm peripheral occlusive disease babycenter llc internet content commerce company devote support community expectant new mother viactiv product line chewable calcium supplement mead johnson nutritional division bristolmyer squibb inverness medical technology acquire enhance control primary supplier lifescan blood glucose monitoring product allow achievement operational synergies acquisition provide key technology development future product approximately million identify value iprd associate inverness medical technology terame inc acquisition iprd charge primarily relate inverness project minimally invasive testing continuous monitoring insulin delivery value iprd calculate assistance party appraiser cash flow projection discount risk inherent project probability success factor range discount rate certain business acquire million acquisition account purchase method accordingly result operation include accompany consolidated financial statement respective date acquisition acquisition include crescendo company form alza purpose select develop commercialize human pharmaceutical product innovasive device company manufacture sell device sport medicine surgery soft tissue injury atrionix inc development stage company primary product pulmonary ablation catheter treatment atrial fibrillation medtrex company develop manufacture electrosurgical generator disposable product joseph aspirin business iprd writeoff associated atrionix inc alza crescendo acquisition million iprd charge primarily relate atrionix project design catheter system procedure block electrical impulse originate pulmonary vein cause atrial fibrillation value iprd calculate assistance party appraiser cash flow projection discount risk inherent project discount rate divestiture material effect company result operation cash flow financial position legal proceeding company involve numerous product liability case unite states concern adverse reaction drug medical device damage claim substantial company confident adequacy warning instruction use accompany product feasible predict ultimate outcome litigation company believe liability result case substantially cover reserve establish selfinsurance program commercially available excess liability insurance group case company concern janssen pharmaceutica product propulsid withdraw general sale restrict limited use wake publicity event numerous lawsuit file janssen wholly own subsidiary company company propulsid state federal court country approximately case currently pende include claim approximately plaintiff recently file mississippi avoid application tort reform legislation effective january case likely file mississippi serve active case individual allege die use propulsid action seek substantial compensatory punitivedamage accuse janssen company inadequately testing warning drug effect promote label use overpromotion addition janssen company enter agreement plaintiff counsel halting run statute limitation respect potential claim significant number individual attorney evaluate sue janssen company behalf september plaintiff rankin case comprise claim propulsid plaintiff go trial state court claiborne county mississippi jury return compensatory damage verdict plaintiff million total million trial judge dismiss claim punitive damage march trial judge reduce verdict total million deny motion janssen company new trial janssen company believe verdict reduce insupportable appeal view janssen company proof trial demonstrate plaintiff injure propulsid basis liability exist april state court judge new jersey deny plaintiff motion certify national class propulsid user purpose medical monitoring refund cost purchase propulsid effort appeal ruling deny june federal judge preside propulsid multidistrict litigation new orleans louisiana similarly deny plaintiff motion certify national class propulsid user plaintiffs multi district litigation say preserve right appeal ruling complaint file janssen company include class action allegation basis future attempt class certify respect propulsid action janssen company dispute claim lawsuit vigorously defend judgment settlement appropriate janssen company believe adequate selfinsurance reserve commercially available excess insurance respect case communication company excess insurance carrier raise certain defense liability policy opinion company defense pro forma lack substance carrier honor obligation policy company ortho biotech subsidiary party arbitration proceeding file amgen ortho biotech licensor nondialysis right procrit amgen seek terminate ortho biotech license right collect substantial damage base allege deliberate procrit sale ortho biotech early amgen reserve dialysis market october arbitrator issue decision reject amgen request terminate license find material breach license arbitrator find conduct ortho biotech early subsequently halt ortho biotech amount nonmaterial breach license award amgen million damage company expense quarter amgen seek billion damage january arbitrator rule amgen prevail party arbitration entitling award reasonable attorney fee cost amgen submit application fee cost company expense million fourth quarter connection outstanding claim patent infringement action try delaware federal court late cordis corporation subsidiary johnson johnson obtain verdict infringement patent validity damage awards boston scientific corporation medtronic ave inc base number cordis coronary stent patent december jury damage action boston scientific return verdict million december jury medtronic ave action return verdict million sum represent lose profit reasonable royalty damage compensate cordis infringement include pre post judgment interest february hearing hold claim boston scientific medtronic ave patent issue unenforceable owe allege inequitable conduct patent office march district judge issue post trial ruling confirm validity enforceability main cordis stent patent claim find certain cordis patent unenforceable district judge grant boston scientific new trial liability damage vacate verdict medtronic ave legal ground appeal federal circuit court appeal underway product johnson johnson operate company subject patent lawsuit potentially affect ability operate company sell product require payment past damage future royalty respect patent challenge generic pharmaceutical firm result introduction generic version product question ensue loss market share follow patent lawsuit concern important product johnson johnson operating company medtronic ave cordis corporation action file april federal court texas assert certain patent own medtronicave cordis velocitytm stent stent structure cyphertm drug elute product trial date set action ortho pharmaceutical barr laboratories inc pende federal court new jersey action file june involve barr effort invalidate ortho patent cover ortho tricyclen oral contraceptive product trial schedule case orthomcneil daiichi inc mylan laboratory orthomcneil daiichi inc teva pharmaceutical matter file february federal court west virginia second june federal court new jersey concern effort mylan teva invalidate establish noninfringement patent cover levaquin levofloxacin tablets patent own daiichi exclusively license orthomcneil mylan case trial set late trial date set teva matter janssen alza mylan laboratory action file federal district court vermont february concern mylan effort invalidate assert noninfringement alza patent cover duragesic product trial likely spring respect matter johnson johnson operate company involve vigorously defend validity assert infringement licensor patent product accuse infringe patent hold defend claim company involve number patent trademark lawsuit incidental business ultimate legal financial liability company respect claim lawsuit proceeding refer estimate certainty opinion management base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company consolidated balance sheet expect material adverse effect company consolidated financial position resolution report period matter significant impact company result operation period earning share follow reconciliation basic net earning share dilute net earning share year end december december december table caption share millions basic earning share average share outstanding basic potential share exercisable stock option plan share repurchase treasury stock method convertible debt share adjust average share outstanding diluted diluted earning share table dilute earning share calculation include dilution effect convertible debt decrease interest expense million million million tax year respectively dilute earning share exclude million share option year million share option year exercise price option great average market valueresulte antidilutive effect dilute earning share capital treasury stock change treasury stock table caption dollar million treasury stock number share thousand share balance january employee compensation stock option plan conversion subordinate debenture repurchase common stock business combination balance december employee compensation stock option plan conversion subordinate debenture repurchase common stock business combination balance december employee compensation stock option plan conversion subordinate debenture repurchase common stock balance december table share common stock authorize issue share end select quarterly financial datum unaudite select unaudited quarterly datum year summarize table caption dollar million second fourth share amount quarter quarter qtr qtr segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share tabletable caption dollar million second fourth share amount quarter quarter qtr qtr segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision table table taxis income net earning basic net earning share dilute net earning share table second quarter include tax charge million relate inprocess research development iprd cost quarter include tax charge million relate amgen arbitration settlement fourth quarter include tax charge million relate amgen legal fee second quarter include tax charge million relate alza merger cost quarter include tax charge million relate alza merger cost fourth quarter include tax charge million relate iprd cost fourth quarter include tax charge million relate lifescan class action settlement subsequent event february johnson johnson announce sign definitive agreement scios inc biopharmaceutical company market product cardiovascular disease research project focus autoimmune disease company acquire scios cash stock exchange term agreement scio shareholder receive outstanding scios share value transaction anticipate closing date expect approximately billion net cash anticipate acquire base scio approximately million fully dilute share outstanding board directors johnson johnson scios give approval transaction subject clearance hartscottrodino antitrust improvement act transaction subject approval shareholder scio customary closing condition scio biopharmaceutical company develop novel treatment cardiovascular inflammatory disease company diseasebase technology platform integrate expertise protein biology computational medicinal chemistry identify novel target rationally design small molecule compound large market unmet medical need scio product natrecor recombinant form naturally occur protein secrete heart body response congestive heart failure chf drug significant advantage exist therapy chf single common cause hospitalization united states patient principal focus scio research development program small molecule inhibitor include potential new treatment pain inflammatory disease include advanced kinase inhibitor program transaction expect close second quarter independent auditor report shareholder board directors johnson johnson opinion accompany consolidated balance sheet relate consolidated statement earning consolidate statement equity consolidate statement cash flow present fairly material respect financial position johnson johnson subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america financial statements responsibility company management responsibility express opinion financial statement base audit conduct audits statement accordance auditing standard generally accept united states america require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion discuss note financial statement company adopt statement financial accounting standard goodwill intangible asset effective december pricewaterhousecooper llp new york new york january note date february segments business johnson johnson subsidiaries table caption sale customer dollar million consumer domestic international total pharmaceutical domestic international total med device diagnostic domestic international total worldwide total table table caption operating profit dollar million consumer pharmaceutical med device diagnostic table table segment total expense allocate segment general corporate worldwide total table table caption identifiable asset dollar million consumer pharmaceutical med device diagnostic segment total expense allocate segment general corporate worldwide total table table caption addition property plant equipment dollar millions consumer pharmaceutical med device diagnostic segment total general corporate worldwide total table table caption depreciation amortization dollar millions consumer pharmaceutical med device diagnostic segment total general corporate worldwide total table geographic area table caption sale customer dollar million united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total table table caption longlive asset dollar million united states europe western hemisphere exclude table table asiapacific africa segment total general corporate non longlived asset worldwide total table management discussion analysis page description segment company business export sale intersegment sale significant sale distributor account total revenue sale concentrated pharmaceutical segment sale procriteprex account total company revenue respectively amount allocate segment include interest incomeexpense minority interest general corporate income expense general corporate include cash marketable security include million inprocess research development iprd million million amgen cost pharmaceutical segment million iprd medical device diagnostic segment include million alza merger cost pharmaceutical segment million iprd million class action settlement medical device diagnostic segment include restructure gain million consumer segment million million iprd charge net restructuring gain pharmaceutical medical device diagnostic segment respectively summary operation statistical data johnson johnson subsidiarie dollar million share figure table caption sale customer domestic sale customer international total sale cost product sell sell marketing admin expense research expense purchase inprocess research develop interest income interest expense net portion capitalize income expense net earning provision taxis income provision taxis income earning cumulative effect accounting change cumulative effect accounting change net tax net earning percent sale customer dilute net earning share common stock percent return average shareholder equity table percent increase decrease previous year table sale customer dilute net earning share supplementary expense datum cost material service total employment costs depreciation amortization maint repair total tax expense table supplementary balance sheet datum table property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand table dollar million share figure table caption sale customer domestic sale customer international total sale cost product sell sell marketing admin expense research expense purchase inprocess research develop interest income interest expense net portion capitalize income expense net earning provision taxis income provision taxis income earning cumulative effect accounting change cumulative effect accounting change net tax net earning percent sale customer dilute net earning share common stock percent return average shareholder equity table percent increase decrease previous year table sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maint repair total tax expense table supplementary balance sheet datum table property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand table adjust reflect twoforone stock split exclude cumulative effect accounting change million earning percent sale customer accounting change earning share accounting change earning percent return average shareholder equity accounting change dilute net earning share percent increase prior year accounting change dilute net earning share increase prior year exclude inprocess research development iprd merger restructuring cost dilute net earning share increase prior year diluted net earning share increase prior year diluted net earning share increase prior year diluted net earning share increase prior year diluted net earning share increase prior year cost product sell include million inventory writeoff restructure percent return average shareholder equity earning percent sale customer dilute net earning share increase prior year period adjust include effect alza merger net interest income include cost material service category include taxis income payroll property business taxis text document document typeex sequence filenameyexvtxt descriptionsubsidiarie text exhibit subsidiary johnson johnson new jersey corporation domestic international subsidiary show certain domestic subsidiary international subsidiary name significant aggregate johnson johnson parent table caption jurisdiction subsidiary organization domestic subsidiary alza corporation delaware alza land management inc delaware biosense webster inc california centocor inc pennsylvania codman shurtleff inc new jersey cordis corporation floridacordis international corporation delaware cordis llc delaware crescendo pharmaceuticals corporation delaware depuy inc delaware depuy acrome inc ohio depuy acrome sale limit partnership massachusetts depuy orthopaedics inc indiana depuy products inc indiana diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery services texas ethicon inc new jersey ethicon llc delaware gynopharma inc delaware heartport inc delaware independence technology llc new jersey innovasive devices inc massachusetts iso merger corp delaware janssen finance company florida janssen inc delaware janssen ortho llc delaware janssen pharmaceutica inc pennsylvania janssen pharmaceutica products new jersey johnson johnson consumer company inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceutical new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development llc new jersey johnson johnson professional inc delaware table table caption jurisdiction subsidiary organization johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida joint medical product corporation delaware jjhc inc delaware lifescan inc california lifescan llc delaware mcneilppc inc new jersey microsphere investments inc delaware ndc investment corporation delaware neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware orapharma inc delaware ortho biologics llc delaware ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products new jersey orthoclinical diagnostics inc new york orthomcneil finance florida orthomcneil pharmaceutical inc delaware roc usa corporation delaware rutan realty llc new jersey splenda inc delaware terame corporation delaware tylenol company new jersey therakos inc florida winthorpe valentine inc delaware international subsidiary abello farmacia italy alza ireland limited ireland apsis sarl france centra medicamenta otc srl italy cilag switzerland cilag international switzerlandcilag mexico mexico cilag holding switzerland cordis europa netherlands cordis italia spa italy cordis medizinische apparate gmbh germany cordis mexico mexico cordis france cordis sarl switzerland depuy ace sarl switzerland depuy australia pty ltd australia depuy france france table table caption jurisdiction subsidiary organization depuy international ltd united kingdom depuy intl holdings ltd united kingdom depuy ireland limited ireland depuy japan japan depuy orthopedie france depuy spa italy depuy holdings limited united kingdom ethicon endosurgery europe gmbh germany ethicon gmbh germany ethicon ireland limited ireland ethicon limited scotland ethicon sas france ethicon spa italy ethnor proprietary limited south africa greiter switzerland greiter international switzerland inverness medical limited scotland janssen animal health bvba belgium janssencilag norway janssencilag sweden janssencilag switzerland janssencilag denmark janssencilag netherlands janssencilag egypt ltd egypt janssencilag venezuela janssencilag farmaceutica ltda brazil janssencilag farmaceutica lda portugal janssencilag farmaceutica srl argentina janssencilag ltd united kingdom janssencilag belgium janssencilag finland janssencilag pharmaceutical saci greece janssencilag pharma gmbh austria janssencilag pty limited australia janssencilag spain janssencilag france janssencilag spa italy janssen farmaceutica mexico janssencilag gmbh germany janssen internationaal cvba belgium janssen korea ltd korea janssenortho inc canada janssen pharmaceutica limited thailand janssen pharmaceutica belgium janssen pharmaceutica pty limited south africa janssen pharmaceutical japan janssen pharmaceutical limited ireland table table caption jurisdiction subsidiary organization healthcare ltd israeljhc nederland netherlands johnson johnson switzerland johnson johnson mexico johnson johnson argentina sace argentina johnson johnson china investment ltd china johnson johnson china ltd china johnson johnson comercio distribuicao ltda brazil johnson johnson consumer france sas france johnson johnson consumer nvsa belgium johnson johnson colombia colombia johnson johnson venezuela venezuela johnson johnson del ecuador ecuador johnson johnson egypt sae egypt johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gmbh germany johnson johnson gesellschaft mbh austria johnson johnson group holdings gmbh germany johnson johnson hellas greece johnson johnson holding sweden johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canada johnson johnson international financial services company ireland johnson johnson international france johnson johnson investments limited united kingdom johnson johnson ireland limited ireland johnson johnson kenya limited kenya johnson johnson kft hungary johnson johnson japan johnson johnson korea ltd korea johnson johnson lda portugal johnson johnson ltd united kingdom johnson johnson limited india johnson johnson msd consumer pharmaceutical sas france johnson johnson management limited united kingdom johnson johnson medical netherlands johnson johnson medical china ltd china johnson johnson medical korea limited korea johnson johnson medical limited united kingdom johnson johnson medical mexico mexico johnson johnson medical nvsa belgium johnson johnson medical pty ltd south africa johnson johnson medical pty limited australia johnson johnson medical shanghai ltd china johnson johnson medical argentina table table caption jurisdiction subsidiary organization johnson johnson morocco morocco johnson johnson new zealand limited new zealand johnson johnson pacific pty ltd australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines johnson johnson poland poland johnson johnson private limited zimbabwe johnson johnson products inc canada johnson johnson produtos profissionais ltda brazil johnson johnson professional products proprietary ltd south africa johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson research pty limited australia johnson johnson mexico johnson johnson spain johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson spolsro czech republic johnson johnson taiwan ltd taiwan johnson johnson thailand ltd thailand johnson johnson venezuela venezuelajohnson johnson zambia limited zambia laboratoires martin johnson johnson msd sas france laboratoire polive snc france lifescan canada ltd canada mcneil consumer nutritional europe switzerland medos switzerland neutrogena limited england neutrogena provence sarl france obtech medical switzerland omj ireland limited ireland omj manufacturing limited ireland orthoclinical diagnostic gmbh germany orthoclinical diagnostic japan orthoclinical diagnostic united kingdom orthoclinical diagnostic belgium orthoclinical diagnostic france orthoclinical diagnostic spa italy penta pty limited australia johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china shanghai johnson johnson limited china tasmanian alkaloid pty ltd australia johnson pharmaceutical research institute switzerland tibotec bvba belgium tibotec pharmaceuticals ltd ireland table table caption jurisdiction subsidiary organization tibotecvirco comm belgium vania expansion snc france woelm pharma gmbh germany xianjanssen pharmaceutical ltd china table text document document typeex sequence filenameyexvtxt descriptionconsent independent accountant text exhibit consent independent accountant consent incorporation reference registration statement form file form file report date january note date february relate financial statement johnson johnson appear annual report shareholder incorporate annual report consent incorporation reference report date january relate financial statement schedule appear pricewaterhousecooper llp pricewaterhousecooper llp new york new york march text document document typeexbsequence filenameyexvwbtxt descriptioncautionary statement text exhibit cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement company time time certain forwardlooking statement publiclyrelease material write oral forwardlooking statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word like plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement furthermore company assume obligation update forwardlooke statement result new information future event development important factor cause company actual result differ company expectation forwardlooke statement follow economic factor include inflation fluctuation interest rate foreign currency exchange rate potential effect fluctuation revenue expense result margin competitive factor include technological advance achieve patent attain competitor new product introduce competitor include fact new competition procrit topselle product company portfolio challenge company patent competitor potentially affect company ability sell product question require payment past damage future royalty generic pharmaceutical firm result introduction generic version product ensue loss market share financial distress bankruptcy experience significant customer supplier impair ability case purchase company product pay product previously purchase meet obligation company supply arrangement impact political economic condition terrorist attack part world military action overseas instability financial market result terrorism military action interruption computer communication system include computer virus impair company ability conduct business communicate internally customer domestic foreign health care change result pricing pressure include continued consolidation health care provider trend manage care health care cost containment government law regulation relate sale promotion reimbursement pricing generally government law regulation affect domestic foreign operation include relate trade monetary fiscal policy taxis price control regulatory approval new product license patent right competition research involve development improvementof new exist product process particularly significant result time time product process obsolescence development new improve product important company success area business difficulty inherent product development include potential inability successfully continue technological innovation complete clinical trial obtain regulatory approval united states abroad gain maintain market approval product possibility encounter infringement claim competitor respect patent intellectual property right preclude delay commercialization product significant litigation adverse company include product liability claim patent infringement claim antitrust claim product efficacy safety concern result product recall regulatory action fda foreign counterpart decline sale impact business combination include acquisition divestiture internally company externally pharmaceutical health care industry issuance new revise accounting standard american institute certify public accountant financial accounting standard board securities exchange commission foregoing list set forth factor impact company ability achieve result describe forwardlooke statement investor understand possible predict identify factor consider list complete statement potential risk uncertainty company identify factor list permit private security litigation reform act text document secdocument end privacyenhance message